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Hypertensive pregnancy disorders (HPD), including preeclampsia and gestational 
hypertension, and gestational diabetes mellitus (GDM) are pregnancy complications associated 
with increased cardiovascular risk in affected women. The primary aims of this research were to 
evaluate the association of HPD and GDM with incident maternal chronic kidney disease (CKD). 
Women were selected from the Coronary Artery Risk Development in Young Adults (CARDIA) 
cohort study who were nulliparous at baseline, delivered at least 1 pregnancy of longer than 20 
weeks’ gestation, and had kidney function measurements during 25 years of follow-up. HPD and 
GDM were self-reported for each interval pregnancy at every CARDIA examination. CKD was 
defined as the development of estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or 
urine albumin to creatinine ratio ³ 25 mg/g at any one CARDIA examination in years 10, 15, 20 
or 25. Hazard ratios (HR) for incident CKD were estimated using complementary log-log 
models, adjusting for pre-pregnancy risk factors (measured at the CARDIA examination prior to 
first pregnancy) for each condition. During a mean follow-up of 20.8 years, 17 of 101 (16.8%) of 
women with GDM developed CKD compared to 88 of 719 (12.2%) of women without GDM 
(p=0.2). There was evidence of a GDM-race interaction on CKD risk (p=0.06). Among black 
women, the adjusted HR for CKD was 1.96 (95% confidence interval (CI), 1.03-3.67). Among 







(11.1%) developed CKD, compared to 31 of 182 (17.0%) of women who reported HPD 
(p=0.04). The adjusted HR for CKD was 1.55 (95% CI 1.00, 2.40) for women with HPD 
compared to those without HPD. Limitations of this study include the small sample size, use of 
single untimed measurements of urine for albumin and creatinine, and some misclassification of 
the exposure, in particular for HPD. In conclusion, GDM is associated with subsequent 
development of CKD among black women. HPD are associated with subsequent development of 
CKD among affected women, with attenuation of the relationship by adjustment for pre-
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CHAPTER 1. INTRODUCTION 
 
Public health burden of chronic kidney disease 
 
 Chronic kidney disease (CKD) is an emerging epidemic in the United States (US) that is 
associated with adverse health outcomes. CKD is defined as abnormalities of kidney structure or 
function, including an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 or a urine 
albumin to creatinine ratio (ACR) ≥ 30 mg/g, that are present for greater than 3 months.1 The 
prevalence of CKD in the US increased from 10.0% to 13.1% from 1988-1994 to 1999-2004.1 
End stage renal disease (ESRD) causes a substantial public health burden in the United States, 
requiring approximately 6% of the Medicare budget for 0.1% of the US population, and patients 
have significant morbidity, mortality and reduced quality of life.2 The risk of cardiovascular 
disease and all-cause mortality among patients with CKD is significant. Reduced eGFR and 
albuminuria are independent risk factors for all-cause mortality, cardiovascular mortality and 
ESRD in the general population.3,4 In a large population-based cohort, among people without 
previous myocardial infarction, the rate of myocardial infarction was significantly higher in 
those with CKD (and no diabetes mellitus (DM)) compared to those with DM (and no CKD) 
suggesting that CKD should be considered a coronary heart disease equivalent.5 In a community-
based prospective cohort study, adding albuminuria to the traditional Framingham risk factors 
significantly improved risk stratification for cardiovascular morbidity and all-cause mortality.6 In 
the same population, elevated urine albumin excretion added to the metabolic syndrome
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 components for prediction of new onset cardiovascular disease and type 2 diabetes mellitus.7 In 
the Heart Outcomes Prevention Study, urine ACR of 9 mg/g was determined to be the optimal 
cutoff for detecting cardiovascular disease risk8, lower than the threshold to diagnose CKD. 
CKD, defined by reduced eGFR and albuminuria, is a significant public health problem due to its 
increasing prevalence and association with ESRD, cardiovascular disease, and death. 
Early detection of CKD allows for both lifestyle and medical interventions, which may 
slow progression of disease and reduce cardiovascular risk, but early stages of CKD are 
asymptomatic.9 In NHANES 1999-2004, only 6.0% of patients with CKD stages 1-4 were aware 
of their disease.10 Lifestyle and medical interventions can both reduce risk of CKD, and slow 
progression of CKD and reduce cardiovascular risk in those affected.2,9,11 Lifestyle interventions 
including dietary salt restriction, weight control, and smoking cessation would be beneficial in 
patients at risk for and with CKD.2,11 Use of angiotensin-converting enzymes inhibitors (ACEIs) 
and angiotensin-receptor blockers (ARBs) has been shown to reduce progression of CKD and 
reduce cardiovascular risk in certain populations.11 Statins and aspirin reduce cardiovascular risk 
in populations with CKD.2 When CKD is detected in early stages, affected patients will benefit 
from interventions to reduce adverse health outcomes. 
Gestational diabetes mellitus (GDM) and hypertensive pregnancy disorders (HPD) affect 
a significant number of pregnancies in the US each year. There are approximately 4,000,000 
births in the US annually.12 GDM affects approximately 6% of pregnancies in the United States 
where the prevalence of GDM has been increasing over time.13,14 Between 1987-2004 in the US, 
preeclampsia affected 2.7% and gestational hypertension 2.1% of deliveries with incidence rates 
increasing over time.15 Thus a significant number of women in the US are diagnosed with GDM 
or HPD each year. In the National Health and Nutrition Examination Survey (NHANES) 1999-
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2004, risk factors of diabetes and hypertension, as well as the presence of proteinuria and male 
gender were associated with awareness of CKD.10 If pregnancy complications are associated 
with CKD, a significant number of women could benefit from an increased awareness of their 
risk for CKD. 
 
Gestational diabetes and chronic kidney disease 
  
 GDM is defined as the onset or first recognition of glucose intolerance during pregnancy. 
GDM is known to predict subsequent development of overt DM.16,17 DM is a well-known cause 
of CKD, but it is unknown if GDM, with or without subsequent diabetes, is a risk factor for 
incident CKD. A call to action from the National Diabetes Education Program recommends 
screening women with GDM for diabetes at 6-12 weeks postpartum, and if normal, screening 
every 3 years and at the start of the next pregnancy.18 For those with pre-diabetes, annual 
screening is recommended. Limited data suggests GDM is associated with microalbuminuria19-22, 
but women are not routinely screened for CKD following a GDM pregnancy. If GDM is 
associated with development of albuminuria or CKD, women should be counseled about this risk 
and screening recommendations should be expanded to include measurement of urine ACR and 
serum creatinine to calculate eGFR. 
Existing studies of GDM and CKD are quite limited. Bomback et al19 evaluated the risk 
of CKD among 37,716 female participants in the Kidney Early Evaluation Program (KEEP) by 
three categories: GDM alone, overt diabetes, and no history of diabetes. KEEP is a community-
based screening program that targets adults at high risk for kidney disease. This study found 
increased odds of CKD stages 1-2 (multivariate odds ratio (OR) (95% confidence interval (CI)) 
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1.54 (1.16-2.05) for women with GDM alone compared to women with no history of diabetes, 
but no increased odds for CKD stages 3-5. This study is limited by its cross-sectional design, so 
that the temporality of the association cannot be assessed and there is a potential for reverse 
causality. Since KEEP is designed to screen participants at high risk of CKD, results may not be 
generalizable to women with lower risk profiles. A single population-based by Kim et al22 using 
cross-sectional data from the Third NHANES compared cardiovascular risk profiles, including 
microalbuminuria, between parous women not currently pregnant who were classified by self-
report as having gestational diabetes but not currently diabetic, who were diabetic, or who were 
unaffected by either condition. Mean levels of ACR were slightly higher in women who reported 
a GDM pregnancy compared to unaffected women (22.4 mg/g compared to 17.0 mg/g), but in 
adjusted analyses, the predicted probability of not having microalbuminuria was slightly, though 
significantly increased (1.05 95% CI 1.01, 1.08) compared to the probability in unaffected 
women. There are several potential explanations for the different results in these two studies. 
NHANES is representative of the civilian, non-institutionalized population of the US, while 
KEEP is targeted to adults at high risk of kidney disease, meaning participants with diabetes, 
hypertension, or family history of diabetes, hypertension or kidney disease. The average age of 
participants was lower in the NHANES population, meaning less time for development of CKD 
since pregnancy.  
In a retrospective study, Friedman et al20 evaluated 72 women 5-8 years after a GDM 
pregnancy and compared them with a control group of 35 women without GDM history. Median 
urinary albumin excretion was higher in the study group compared to the control group 
(p<0.0001), but only 30.5% of women had microalbuminuria, all in the study group. The only 
prospective study of GDM and CKD, by Go et al,21 evaluated a cohort of 289 African American 
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women with GDM at a median of 11 years after delivery and reported a microalbuminuria 
prevalence of 11% in normoglycemic women versus 36% in women who developed overt DM 
after GDM. There was no comparison group of women without a history of GDM.  
This study is the first prospective population-based study of GDM and incident CKD, and 
improves upon the existing literature in several ways. This study is a secondary data analysis 
using the Coronary Artery Risk Development in Young Adults Study (CARDIA). First, although 
GDM pregnancy was assessed by self-report in CARDIA as in NHANES and KEEP, a 
validation study by Gunderson et al23 was conducted among 165 CARDIA women by abstracting 
medical records of 200 births showing sensitivity of 100% and specificity of 92% for self-report 
of ever having GDM. Second, CARDIA has 25 years of follow-up, which is an adequate 
duration of follow-up after a pregnancy affected by GDM for the development of kidney disease. 
Finally, repeated measures of kidney function were obtained in CARDIA, which allowed 
assessment of changes in kidney function over time in participants with and without a history of 
GDM. 
 
Hypertensive pregnancy disorders and chronic kidney disease 
 
 Preeclampsia is a multisystem disorder defined by the onset of elevated blood pressure 
and proteinuria after 20 weeks’ gestation.24 Newer criteria allow for the diagnosis of 
preeclampsia in the absence of proteinuria if there is evidence of other end-organ damage.25 It is 
hypothesized that the placenta secretes several anti-angiogenic factors in higher quantities during 
preeclamptic pregnancies, and a resultant imbalance in pro-angiogenic and anti-angiogenic 
factors may trigger abnormal placental vascular development and onset of endothelial 
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dysfunction.26 Glomerular endotheliosis, increased vascular permeability and a systemic 
inflammatory response lead to end-organ damage and hypoperfusion, which results in the 
clinical manifestations of hypertension, proteinuria and decreased kidney function.27 The 
glomerular endothelial dysfunction may be persistent and lead to development of chronic kidney 
disease.28 Gestational hypertension is defined by the onset of elevated blood pressure without 
proteinuria after 20 weeks’ gestation.24 Nearly half of women diagnosed with gestational 
hypertension between 24 and 35 weeks develop preeclampsia.29 Preeclampsia and gestational 
hypertension share risk factors, including DM, renal or cardiac disease, prior preeclampsia, 
urinary tract infection, twin pregnancy and obesity.30 Both are associated with increased risk for 
fetal death and severe neonatal morbidity and mortality.30 Thus, preeclampsia and gestational 
hypertension may be related in pathogenesis. HPD may be associated with incident CKD, but no 
formal recommendations exist for screening women with a history of these disorders for CKD, 
or for counseling them about their potential risk for CKD. 
Large population based-studies have shown an increased risk for later kidney biopsy and 
an increased risk of subsequent ESRD among women with a history of preeclampsia.31,32 In a 
study of all first singleton deliveries in Norway between 1967-1998, women with a history of 
preeclampsia had a significantly increased risk of later kidney biopsy compared to women 
without a history of preeclampsia.31 A similar study including data on up to 3 singleton deliveries 
between 1967 and 2004 in Norway found increased relative risk (RR) of ESRD for women with 
preeclampsia during any one pregnancy or combination of pregnancies compared to women 
without a history of preeclampsia.32 There are several possible explanations for the results of 
these studies. CKD is a risk factor for preeclampsia33,34 and thus undetected baseline CKD could 
explain these findings. In the study of later kidney biopsy, the increased risk for kidney biopsy in 
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women with a history of preeclampsia was greatest in the first five years after pregnancy, which 
would support this hypothesis. Additionally, the kidneys had a variety of pathologic findings, 
and history of preeclampsia was not associated with any one specific type. Another possibility is 
that shared risk factors for preeclampsia and CKD could explain any association between the two 
entities. Risk factors for preeclampsia include hypertension, diabetes, and obesity35 all of which 
are well-known risk factors for CKD.9 The increased risk of later kidney biopsy in the mother 
with a history of preeclampsia was similar when women with known diabetes, kidney disease 
and rheumatic disease before pregnancy were excluded although there was no pre-pregnancy 
measurement of microalbuminuria or GFR available. Additionally, there was no information on 
potential confounders such as blood pressure and maternal body weight. Finally, preeclampsia 
itself may damage the kidneys with scarring or incomplete healing from glomerular 
endotheliosis.36 This scarring would lead to microalbuminuria and likely with time, a decline in 
kidney function. Several studies, described below, have found persistent microalbuminuria 
following preeclampsia37-47 which would suggest this possibility. However, limitations to these 
studies, such as limited adjustment of confounding or an inability to exclude underlying CKD 
mean that the mechanism underlying the association between preeclampsia and CKD is still 
uncertain. 
A meta-analysis of 7 cohort studies of kidney disease after preeclampsia found an 
increased risk of microalbuminuria at a weighted mean of 7.1 years postpartum.42 A weighted 
average of 31% of women with a history of preeclampsia had microalbuminuria, compared to 
7% women with no history of preeclampsia, resulting in an unadjusted relative risk (RR) of 4.31 
(95% CI 2.70-6.89). When albuminuria was assessed as a continuous outcome there were higher 
values of albuminuria in women with a history of preeclampsia, with a mean difference of 8.55 
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mg/24 hrs (95% CI 2.11-14.98). There was no difference in estimated GFR (eGFR) or serum 
creatinine concentrations between women with and without a history of preeclampsia. Three 
studies had another comparison group of women with a history of gestational hypertension. 
Women with preeclampsia had an increased risk of microalbuminuria compared to women with 
gestational hypertension (RR 2.2, 95% CI 1.17-4.13), and women with gestational hypertension 
had an increased risk of microalbuminuria compared to unaffected women (RR 2.51, 95% CI 
0.67-9.32). There was significant heterogeneity in the pooled estimates for albuminuria as a 
continuous and dichotomous outcome. Other limitations included small sample size, with a total 
of 273 women with preeclampsia, 135 women with gestational hypertension and 333 without 
included in the meta-analysis. Most studies were single center, and the studies took place in 
Israel37, Belgium39, Jordan46, New Zealand44 and Scandinavia.38,40,43 One study was limited to 
women with HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome39 and another 
examined the risk of diabetic nephropathy in women with type 1 DM after pregnancies with and 
without preeclampsia.38 Only one study provided adjusted estimates38, although other studies 
attempted to control for potential confounders by exclusion, matching or comparison between 
women with and without preeclampsia history. Many potential confounders such as race, obesity 
and smoking status were not routinely included.  
Several small studies have been published since the meta-analysis examining the same 
association. Mangos et al41 examined 101 Australian women with a history of preeclampsia, 
gestational hypertension and normal pregnancies 2-11 years post-partum, and found no 
difference in urine ACR and eGFR among the three groups 4-5 years postpartum. Since 
endothelial dysfunction is hypothesized as a potential cause of increased cardiovascular disease 
risk and increased risk for kidney disease following a pregnancy affected by preeclampsia, the 
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authors also measured endothelial function using strain gauge plethysmography of forearm blood 
flow after occlusion and found no differences between groups. Spaan et al47 compared 22 
formerly preeclamptic women with 29 parous controls who delivered at a single center in the 
Netherlands 23 years postpartum, and found decreased creatinine clearance, effective renal blood 
flow, and effective renal plasma flow as well as increased renal vascular resistance. There was 
no difference in microalbuminuria between groups, although overall there was a low incidence of 
microalbuminuria. Shabhazian et al45 compared 35 women with a history of preeclampsia to 35 
parous women with uncomplicated pregnancies who delivered at 2 centers in Iran. The authors 
found that 20% of women with a history of preeclampsia had microalbuminuria compared to 
none of the comparison group (p<0.001). Bokslag et al48 compared 131 women with early-onset 
preeclampsia in Amsterdam, The Netherlands with 56 controls and found greater levels of 
albuminuria. Sandvik et al49 compared 89 women with and 69 women in Bergen, Norway 
without preeclampsia and found no association with albuminuria 10 years following pregnancy.   
Two larger population-based studies of hypertensive disorders of pregnancy and CKD 
were recently published.50,51 Mannisto et al50 studied 10,314 women with singleton pregnancies 
from the Northern Finland Birth Cohort 1966, which included all expected births for the year 
1966 in 2 northern Finland provinces. The authors grouped women into mutually exclusive 
categories describing blood pressure in pregnancy, including normotensive, isolated systolic 
hypertension, isolated diastolic hypertension, isolated systolic or diastolic hypertension with 
proteinuria, gestational hypertension and preeclampsia/eclampsia. Average follow-up time was 
39.4 years and the outcome of CKD was defined by disease-specific International Classification 
of Diseases (ICD) codes recorded in Finnish registers. Women with isolated systolic or diastolic 
hypertension with proteinuria (hazard ratio (HR) 2.83, 95% CI 1.02-7.90) and women with 
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gestational hypertension (HR 1.91, 95% CI 1.18-3.09) had increased risk for CKD compared to 
normotensive women. There was no increased risk for CKD among women with preeclampsia 
compared to normotensive women but there was lower statistical power for this analysis. Results 
were similar in sensitivity analyses excluding women with known risk factors for cardiovascular 
disease, such as smoking, overweight/obesity, advanced age and diabetes mellitus. This study did 
collect data prospectively during pregnancy, such that exposure categorization was likely 
reliable. Wang et al51 used reimbursement claims from the Taiwan National Health Insurance 
Program to study incident CKD and ESRD among 26,651 women with a history of hypertensive 
disorders of pregnancy between 1998 and 2009, with follow-up through December 31, 2009 for 
the outcome. The comparison group was 213,397 women randomly selected and frequency 
matched by age and index year of pregnancy. Women with a history of hypertension, diabetes, 
renal disease and systemic lupus erythematous before the index date were excluded. Exposure 
and outcome assessment were defined by ICD codes, and hypertensive disorders of pregnancy 
were considered one exposure category. Among women with any hypertensive disorder of 
pregnancy, the adjusted HR was 9.38 (95% CI 7.09, 12.4). Follow-up time after pregnancy was 
short, and information on individual level data, including information on smoking, educational 
level, BMI and marital status, was lacking. Both studies are subject to outcome misclassification 
bias, as ICD codes for kidney disease often fail to identify patients with eGFR < 60 
ml/min/1.73m2.52-54 Women with preeclampsia may be more likely to have follow-up resulting in 
a diagnosis of kidney disease, which would bias results away from the null. 
De Paauw et al55 expanded on prior research in a sub-analysis of the Prevention of Renal 
and Vascular Endstage Disease (PREVEND) Study, a Dutch population-based cohort study with 
prospective data for kidney function and albuminuria. A total of 977 women who reported HPD 
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at the first PREVEND visit were compared to 1,805 women without HPD. Median follow-up 
time was 11 years and women were aged 39 to 59 at the first visit. The study found that blood 
pressure was significantly higher in the HPD group compared to the unaffected women. The use 
of antihypertensive medication use as well as angiotensin-converting enzyme (ACE) 
inhibitors/angiotensin receptor blockers (ARBs) was also higher at baseline in the HDP group. 
The percentage of women developing CKD was comparable in the groups (HR 1.04, 95% CI 
0.79-1.37) although there was a steeper decline in eGFR slope in the HPD group compared to the 
non-HPD group. This pattern disappeared after accounting for ACE inhibitor/ARB effect. There 
was no difference in 24-hour albuminuria between groups. ACE inhibitors and ARBs are known 
to reduce proteinuria56-58 so higher ACE inhibitor/ARB use in the HPD group could in part 
explain the findings in this study. Pre-pregnancy measurements of potential confounders of the 
HPD-CKD association were not available in this study. 
One study of the HPD-CKD association has been published in a US population.  
Kattah et al59 studied 3015 women who participated in the second Family Blood Pressure 
Program Study visit (2000-2004) and had measures of kidney function available. This study 
found that women with HPD were more likely to have hypertension, diabetes, and higher body 
mass index compared to women who reported normotensive pregnancies. There was a greater 
risk of urine albumin/creatinine ratio > 25 mg/g in those who reported at least one pregnancy 
with hypertension (OR 1.37, 95% CI 1.02-1.85) compared to women with normotensive 
pregnancies, after adjustment for education status, smoking status, current hypertension, use of 
ACE inhibitors/ARBs, use of hormone replacement therapy, diabetes mellitus, log(BMI) and 
family history of hypertension and CVD, age, race, and network. Although this study did 
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consider confounders of the HPD-CKD relationship, they were not measured prior to pregnancy. 
Kidney function was measured at a single time point.   
A nested case-control study used the US Renal Data System to identify women with 
ESRD from a cohort of 34,581 women who gave birth in 1976-2010 in Olmstead County, 
Minnesota, from which 44 cases of ESRD were identified and each matched to 2 controls based 
on year of birth, age at first pregnancy and parity.60 Pre-pregnancy data was available from the 
Rochester Epidemiology Project, which captures health care information for individuals who are 
residents of Olmstead County. The unadjusted OR for ESRD was 4.0 (95% CI, 1.21-13.28) for 
women with preeclampsia compared to women without preeclampsia, with similar results after 
independent adjustment for race, education, diabetes or hypertension prior to pregnancy. 
However, the association was attenuated after adjustment for obesity measured prior to 20 weeks 
at any first pre-natal visit (OR 3.25, 95% CI 0.93-11.37). Pre-existing kidney disease was present 
prior to first pregnancy in 9 of 44 cases (21%). The number of cases of ESRD was small, 
limiting power.  
Results of the above studies should be replicated in other study populations, with 
extended length of follow-up, adjustment for pre-pregnancy confounders of the HPD-CKD 
association, and improved outcome ascertainment. CARDIA includes a diverse population of 
black and white young adults who have been followed for 25 years. Rather than using ICD codes 
to define CKD, serum creatinine, used to estimate GFR, and urine albumin and creatinine have 
been measured at multiple CARDIA exams. Pre-pregnancy data is available for shared risk 
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 This was an ancillary study using data from the Coronary Risk Development in Young 
Adults (CARDIA) Study. CARDIA is a prospective population-based cohort study that enrolled 
5,115 black and white participants (2,801 women) aged 18-30 in 1985-86 and examined them at 
2, 5, 7, 10, 15, 20 and 25 years after the baseline exam. Participants were recruited from 
Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA to obtain a representative 
sample of the underlying populations of young adults, with stratification to achieve equal 
numbers of males and females, blacks and whites, persons <25 and ≥25 years of age, and persons 
with high school graduation or less and more than high school education.1 All participants gave 
informed consent, and the appropriate institutional review boards approved the study.  
 
Study population  
 
Women were asked at each cohort examination whether they were currently pregnant or 
breastfeeding, and about the number of pregnancies, abortions, miscarriages, still births and live 
births since the last exam. The first reported pregnancy longer than 20 weeks’ gestation was 
treated as the index pregnancy. Women were included in the analytic cohort at the examination 
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before the index pregnancy, and all covariates were selected from that examination. Women who 
reported a first birth before the 10-year follow-up examination had their covariates assessed at 
the first CARDIA examination. For a woman who reported her first birth at CARDIA 
examination year 20, pre-pregnancy covariates were selected from the prior examination in year 
15.  
 
Gestational diabetes mellitus 
 
As shown in Figure 2.1, women were excluded who were parous at the initial CARDIA 
examination (N=1008), women with zero births at the end of CARDIA follow-up (examination 
year 25, N=862), women with CKD prior to or at the baseline examination (N=7), women with 
diabetes mellitus prior to any pregnancy (N=3), women missing measurements of baseline CKD 
or missing measures of both albuminuria and eGFR at all four examinations where the outcome 
was measured (N=25), and women missing data for covariates of interest (N=30). Baseline CKD 
was defined as eGFR < 60 ml/min/1.73 m2 or self-reported kidney disease other than 
nephrolithiasis or pyelonephritis or urine albumin-creatinine ratio (ACR) ³ 25 mg/g adjusted for 
race and sex (urine ACR was not measured at the initial examination). 
 
 Hypertensive pregnancy disorders 
 
As shown in Figure 2.2, women were excluded who were parous at the initial CARDIA 
examination (n=1,008), women with zero reported births at the CARDIA examination in year 25 
(n=862), women with hypertension prior to any pregnancy (n=29), women with CKD before or 
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at the baseline examination or missing measures of CKD at baseline (n=36), women missing 
measures of both albuminuria and eGFR at all 4 examinations at which the outcome was 
measured (n=25), and women missing data for covariates of interest (n=20). Baseline CKD was 
defined as eGFR < 60 ml/min/1.73 m2 or self-reported kidney disease other than nephrolithiasis 
or pyelonephritis or urine albumin-creatinine ratio (ACR) ³ 25 mg/g adjusted for race and sex 




Gestational diabetes mellitus 
 
 At each examination, women were asked if they had diabetes and whether they had 
diabetes only during pregnancy. Self-report of GDM was validated for 200 births between 
baseline and year 10 in 165 CARDIA women by medical record abstraction of laboratory data. 
The sensitivity of reports of ever having GDM was 100% (20 of 20) and specificity was 92% 
(134 of 145).2 
 Women were included if nulliparous (no live births of > 20 weeks gestation) at baseline, 
and transitioned across follow-up time intervals (0-10, >10-15, >15-20, and >20-25) in which the 
number of births (parity) and GDM status were updated. The number of births was cumulative to 
the end of follow up (i.e. examination year of development of CKD or year 25). Once women 
developed GDM, they were classified as having GDM for all subsequent follow-up time (which 
may have included additional pregnancies).  
 
 23 
Hypertensive pregnancy disorders 
 
At each CARDIA examination, women were asked if they were currently pregnant or 
breastfeeding, and about the number of pregnancies in the interval since the last exam. For each 
interval pregnancy, women were asked if they had toxemia, including all of the following: high 
blood pressure, albumin in the urine and swelling of the ankles, or high blood pressure without 
toxemia. At year 10, an ancillary study was conducted called Hypertension in Pregnancy (HIP). 
In this study, women completed a questionnaire reporting whether they had toxemia or high 
blood pressure during each prior pregnancy. Self-report of an HPD was validated for 366 
pregnancies between baseline and year 10 in 290 CARDIA women by medical record abstraction 
of antepartum and intra-partum blood pressures, urinary protein levels, medication use and 
International Classification of Diseases, 9th Revision (ICD-9) codes. The gold standard for 
preeclampsia was defined as elevated blood pressure and 1+ proteinuria on two or more 
occasions after 20 weeks’ gestation and/or medications specifically used to treat preeclampsia 
before and/or during labor and/or ICD-9 codes 642.4-642.5. Self-report of preeclampsia had a 
sensitivity of 36% and specificity of 93%.3 The gold standard for gestational hypertension was 
defined as elevated blood pressure and absence of 1+ proteinuria on two or more occasions after 
20 weeks’ gestation and/or discharge diagnosis ICD-9 code of 642.3. For any HPD, the 
sensitivity of self-report was 40% with negative predictive value of 90%.4   
 Included women were nulliparous (no live births of > 20 weeks’ gestation) at baseline 
and transitioned across follow-up intervals (0-10, >10-15, >15-20, and >20-25 years) in which 
the number of births and HPD status were updated. The number of births was cumulative to the 
end of follow up (i.e. examination year of development of CKD or year 25). Once women 
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developed an HPD, they were classified as having a HPD for all subsequent follow-up time 
(which may have included additional pregnancies). Preeclampsia and gestational hypertension 
were combined to form one exposure to increase study power. Both have similar risk factors and 
are associated with increased risk for fetal death and severe neonatal morbidity and mortality.5 
Nearly half of women diagnosed with gestational hypertension between 24 and 35 weeks of 
pregnancy go on to develop preeclampsia.6 Thus, preeclampsia and gestational hypertension may 




 CARDIA participants provided single untimed urine specimens for measurement of urine 
albumin and creatinine at the year 10, 15, 20 and 25 examinations. Urine albumin was measured 
by nephelometry with a specific anti-albumin monoclonal antibody. In years 10, 15, and 20, 
urine creatinine was measured by the Jaffe method and in year 25 by the Roche enzymatic 
method. Calibration constants were developed based on creatinine excretion across 3 days of 24-
hour urine collections in a CARDIA subsample (n-839).7 These constants were used in our study 
as in Murtaugh et al8 to adjust for sex- and race-specific differences in urine creatinine excretion 
using the formula albumin / (k x creatinine), where k=0.88 in black women (no adjustment 
required for female sex). 
 Blood samples were drawn from seated participants after at least 8 hours of fasting. 
Serum creatinine was measured at years 0, 10, 15, and 20 by the modified-rate Jaffe method and 
in year 25 by the Roche enzymatic method. All samples were calibrated to National Institute of 
Standards and Technology as recommended by the National Kidney Disease Education Program 
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Laboratory Working Group.9 eGFR was calculated using the CKD-EPI (CKD Epidemiology 
Collaboration) creatinine equation.10 The accuracy of the CKD-EPI equation in individuals with 
and without kidney disease, with a wide range of kidney function, clinical characteristics and 
racial backgrounds has been documented.10,11  
 Incident CKD was defined in this study as the development of eGFR < 60 ml/min/1.73m2 
or urine ACR ³ 25 mg/g at any one CARDIA examination in years 10, 15, 20 and 25. In 
examination years in which only one CKD measure was available for an individual, either eGFR 




Information on race, sex, and age was self-reported, and trained interviewers assessed 
sociodemographic information including highest level of education completed, medical history, 
family history and medication use. Education level, measured at each examination, was used as a 
measure of socioeconomic status, and categorized as high school or less or more than high 
school. Physical activity was assessed using the interviewer-administered CARDIA Physical 
Activity History assessment at each examination.12 Family history of diabetes mellitus was 
defined by a report of one or more first-degree relatives having diabetes mellitus at one or more 
examinations and family history of CKD was defined as report of one or more first-degree 
relatives with kidney disease.  
Sitting blood pressure was measured by trained technicians who chose the cuff size 
appropriate to the arm circumference. After an initial 5-minute rest, blood pressure was 
measured three times at 1-minute intervals using the Hawksley (Lancing, Sussex, UK) random-
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zero sphygmomanometer through year 15 and the oscillometric Omron (Omron Corp., 
Schaumberg, IL) HEM907XL in years 20 and 25. Calibration equations were established to 
calibrate the Omron measurements to the random-zero device.3 The average of the second and 
third measurements were used. Hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg or use of antihypertensive medications. 
Weight and height were recorded at each examination, to the nearest 0.5 cm and nearest 
0.2 kg, respectively.13 BMI was computed as weight in kilograms divided by squared height in 
meters.   
Glucose was measured using the hexokinase ultraviolet method at years 0, 10, 15 and 20 
using hexokinase coupled to glucose-6-phosphate dehydrogenase.14 At year 25 fasting glucose 
was measured by the Roche Modular P hexokinase method. Blood lipids and lipoproteins were 
measured at each examination.15 Total cholesterol and triglycerides (TG) were measured 
enzymatically, high-density lipoprotein cholesterol (HDL-C) was determined by precipitation 
with dextran sulfate-magnesium chloride, and LDL-C was calculated using the Friedewald 
equation.15 Diabetes mellitus was defined as a fasting glucose ≥ 126 mg/dl, hemoglobin A1c ≥ 
6.5%, 2 hour oral glucose tolerance test (OGTT)  ≥  200 mg/dl and/or use of diabetes 
medications. Glucose intolerance was defined as fasting plasma glucose ≥ 100 mg/dl, 2 hour 
OGTT ≥ 140 mg/dl or use of diabetes medications. Insulin resistance was defined as TG/HDL-C 
≥ 1.7 for black women and TG/HDL-C ≥ 2.2 for white women16 or by the Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR).17,18 Metabolic syndrome was defined as any 3 of 
waist girth > 88 cm, TG ≥ 150 mg/dl, HDL-C < 50 mg/dl, SBP ≥ 130 or DBP ≥ 85 or use of 





Gestational diabetes mellitus 
 
 Baseline characteristics were compared between women with and without reported GDM 
pregnancies. Pre-pregnancy characteristics correspond to the examination at the beginning of the 
interval during which a woman first reports a birth, where the intervals are CARDIA exam years 
0-10, 10-15, 15-20, 20-25. The probability of not having CKD at each time interval was 
calculated by product limit estimation, and cumulative incidence of CKD within each time 
interval was calculated as 1 minus survival, for parous women with and without exposure to 
GDM.  To account for interval censored data, complementary log-log models were used to 
estimate hazard ratios (HR) of CKD by the method of Prentice and Gloecker,19 comparing 
women with and without a history of GDM. Confounders were chosen a priori based on a 
directed acyclic graph (see Appendix 1).20 DAGgity21 was used to determine the minimally 
sufficient set, which included baseline (from the CARDIA exam prior to first pregnancy) age, 
race,  smoking, dyslipidemia, systolic blood pressure, BMI, physical activity score, and 
education level (for socioeconomic status) as well as any report of family history of diabetes. 
Additionally, baseline fasting glucose and eGFR were included in the adjusted model. Effect 
measure modification between race and the exposure was calculated by the addition of an 
interaction term to each model and considered significant for likelihood ratio tests (LRT) with p-
values less than 0.1. To analyze change in eGFR over time, percent annualized decline in eGFR 
was calculated for each interval and used as the outcome measure in linear mixed models. Linear 
mixed models were chosen to account for within-subject correlation of repeated measure using 
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the autoregressive (1) correlation structure based on corrected Akaike Information Criterion. The 
same minimally sufficient set of baseline confounders was included in the adjusted model, as 
well as baseline fasting glucose and eGFR. Analyses were conducted using SAS version 9.4 
(Cary, NC) and type 1 error was set at 5% level of significance for two-sided tests.  
 
Hypertensive pregnancy disorders 
 
Baseline characteristics were compared between women with and without reported HPD. 
Pre-pregnancy characteristics correspond to the examination at the beginning of the interval 
during which a woman first reports a birth, for which the intervals are CARDIA examination 
years 0 to 10, 10 to 15, 15 to 20, and 20 to 25. To account for interval-censored data, 
complementary log-log models were used to estimate HRs of CKD by the method of Prentice 
and Gloecker19, comparing women with and without a history of HPD. Confounders were chosen 
a priori based on a directed acyclic graph (See Appendix 1).20 DAGitty21 was used to determine 
the minimally sufficient set, which included baseline (from the CARDIA examination before the 
first pregnancy) age, race, smoking, dyslipidemia, SBP, BMI, physical activity score and 
education level (for socioeconomic status). Additionally, baseline eGFR was included in the 
adjusted model. As normal pregnancy affects renal physiology resulting in an increase in eGFR 
and small increase in proteinuria,22 measures of CKD were set to missing for any examination 
year when a woman was pregnant. Effect measure modification between race and the exposure 
was calculated by the addition of an interaction term to each model and considered significant 
for likelihood ratio tests (LRT) with p-values less than 0.1. Analyses were conducted using SAS, 




Gestational diabetes mellitus 
 
 Normal pregnancy affects renal physiology, resulting in an increase in eGFR and a small 
increase in albuminuria.22 As a sensitivity analysis, measures of CKD were set to missing for any 
examination year when a woman was pregnant, and complementary log-log models were again 
used to estimate hazard ratios (HR) of CKD. Women with pregnancies before the initial 
CARDIA exam who also reported interim births during follow-up (N=387) were included in a 
sensitivity analysis with the main study sample (total N=1207 for this analysis). Only births 
occurring after the initial CARDIA examination were considered, and covariates were taken 
from the CARDIA examination at the beginning of the interval during which women reported 
their first interim birth. Lastly, the analysis was repeated considering only women with 
albuminuria as the outcome.  
 
Hypertensive pregnancy disorders 
 
 We used Bayesian methods to correct for the effect of exposure misclassification as 
described in detail by Gustafson23 and MacLehose et al24 demonstrated by Keil et al25 for time-
fixed exposures. A Bayesian approach was chosen as it could be implemented straightforwardly 
with a complementary log-log model and time-varying exposures. This approach uses 3 jointly 
estimated sub-models to quantify the association between the “true” exposure and estimate its 
association with CKD. One sub-model was used to model the probability of the “true” exposure 
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as a function of all the covariates in a logistic model. To simplify the analysis, the only 
covariates included beyond the effect of HPD and the intervals were age, race and BMI. Prior 
estimates for regression parameters were given normally distributed priors with a mean of 0 and 
a variance of 5 (N (0,5)).  The second model estimated the probability of the measured exposure, 
given the “true” exposure and prior parameter estimates of exposure misclassification (sensitivity 
and false positive probability). The third model estimated the probability of a participant in the 
study being diagnosed with CKD as a function of the “true” exposure and all covariates. These 
probabilities were then used to estimate the posterior HR and 95% credible intervals of the HPD-
CKD association. We assumed sensitivity and specificity were uncorrelated across time within 
individuals. Priors for sensitivity and specificity were derived from the CARDIA validation 
study among nulliparous women at baseline. We also explored priors based on other validation 
studies of HPD reported in the literature. Validation studies were selected that used a similar 






























































Abbreviations: ACR, albumin to creatinine ratio; CARDIA, Coronary Artery Risk Development 





Total CARDIA participants at initial 
exam in 1985-86 
n=5115 




Parous at initial CARDIA exam 
n=1008 
Zero births during follow-up 
n=862 
Missing serum Cr at baseline 
exam n=29 
CKD at or prior to baseline exam 
n=7 
Diabetes mellitus prior to any 
pregnancy n=3 
Missing both urine ACR and 
serum Cr at all of year 10, 15, 20 
and 25 exams n=25 













Abbreviations: ACR, albumin to creatinine ratio; CARDIA, Coronary Artery Risk Development 









1. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and 
some characteristics of the examined subjects. Journal of clinical epidemiology 1988;41:1105-
16. 
2. Gunderson EP, Lewis CE, Tsai AL, et al. A 20-year prospective study of childbearing 
and incidence of diabetes in young women, controlling for glycemia before conception: the 
Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes 2007;56:2990-
6. 
3. Gunderson EP, Chiang V, Lewis CE, et al. Long-term blood pressure changes measured 
from before to after pregnancy relative to nonparous women. Obstetrics and gynecology 
2008;112:1294-302. 
4. Catov JM, Ness RB, Wellons MF, Jacobs DR, Roberts JM, Gunderson EP. Prepregnancy 
lipids related to preterm birth risk: the coronary artery risk development in young adults study. 
The Journal of clinical endocrinology and metabolism 2010;95:3711-8. 
5. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and 
intrauterine growth restriction, related or independent conditions? American journal of obstetrics 
and gynecology 2006;194:921-31. 
6. Barton JR, O'Brien J M, Bergauer NK, Jacques DL, Sibai BM. Mild gestational 
hypertension remote from term: progression and outcome. American journal of obstetrics and 
gynecology 2001;184:979-83. 
7. Jacobs DR, Jr., Murtaugh MA, Steffes M, Yu X, Roseman J, Goetz FC. Gender- and 
race-specific determination of albumin excretion rate using albumin-to-creatinine ratio in single, 
untimed urine specimens: the Coronary Artery Risk Development in Young Adults Study. 
American journal of epidemiology 2002;155:1114-9. 
8. Murtaugh MA, Jacobs DR, Jr., Yu X, Gross MD, Steffes M. Correlates of urinary 
albumin excretion in young adult blacks and whites: the Coronary Artery Risk Development in 
Young Adults Study. American journal of epidemiology 2003;158:676-86. 
9. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine 
measurement: a report from the Laboratory Working Group of the National Kidney Disease 
Education Program. Clinical chemistry 2006;52:5-18. 
 34 
10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Annals of internal medicine 2009;150:604-12. 
11. Padala S, Tighiouart H, Inker LA, et al. Accuracy of a GFR estimating equation over 
time in people with a wide range of kidney function. American journal of kidney diseases : the 
official journal of the National Kidney Foundation 2012;60:217-24. 
12. Anderssen N, Jacobs DR, Jr., Sidney S, et al. Change and secular trends in physical 
activity patterns in young adults: a seven-year longitudinal follow-up in the Coronary Artery 
Risk Development in Young Adults Study (CARDIA). American journal of epidemiology 
1996;143:351-62. 
13. Lewis CE, Smith DE, Wallace DD, Williams OD, Bild DE, Jacobs DR, Jr. Seven-year 
trends in body weight and associations with lifestyle and behavioral characteristics in black and 
white young adults: the CARDIA study. American journal of public health 1997;87:635-42. 
14. Gunderson EP, Jacobs DR, Jr., Chiang V, et al. Duration of lactation and incidence of the 
metabolic syndrome in women of reproductive age according to gestational diabetes mellitus 
status: a 20-Year prospective study in CARDIA (Coronary Artery Risk Development in Young 
Adults). Diabetes 2010;59:495-504. 
15. Bild DE, Jacobs DR, Liu K, et al. Seven-year trends in plasma low-density-lipoprotein-
cholesterol in young adults: the CARDIA Study. Annals of epidemiology 1996;6:235-45. 
16. Kats D, Knowles JW, Reaven GM, Sharrett AR, Nambi V, Heiss G. Abstract MP37: The 
Triglyceride to High-density Lipoprotein Cholesterol Ratio, an Estimate of Insulin Resistance, is 
Associated with Incident Coronary Heart Disease. The Atherosclerosis Risk in Communities 
(ARIC) Study. Circulation 2016;133:AMP37. 
17. Gunderson EP, Quesenberry CP, Jr., Jacobs DR, Jr., Feng J, Lewis CE, Sidney S. 
Longitudinal study of prepregnancy cardiometabolic risk factors and subsequent risk of 
gestational diabetes mellitus: The CARDIA study. American journal of epidemiology 
2010;172:1131-43. 
18. Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify 
insulin resistance. Atherosclerosis 2008;196:696-703. 
19. Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application 
to breast cancer data. Biometrics 1978;34:57-67. 
 35 
20. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. 
Epidemiology (Cambridge, Mass) 1999;10:37-48. 
21. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. 
Epidemiology (Cambridge, Mass) 2011;22:745. 
22. Odutayo A, Hladunewich M. Obstetric nephrology: renal hemodynamic and metabolic 
physiology in normal pregnancy. Clinical journal of the American Society of Nephrology : 
CJASN 2012;7:2073-80. 
23. Gustafson P, Le ND, Saskin R. Case-control analysis with partial knowledge of exposure 
misclassification probabilities. Biometrics 2001;57:598-609. 
24. MacLehose RF, Olshan AF, Herring AH, Honein MA, Shaw GM, Romitti PA. Bayesian 
methods for correcting misclassification: an example from birth defects epidemiology. 
Epidemiology (Cambridge, Mass) 2009;20:27-35. 
25. Keil AP, Daniels JL, Hertz-Picciotto I. Autism spectrum disorder, flea and tick 
medication, and adjustments for exposure misclassification: the CHARGE (CHildhood Autism 
Risks from Genetics and Environment) case-control study. Environmental health : a global 
access science source 2014;13:3. 
 
	 36	
CHAPTER 3. RESULTS – GESTATIONAL DIABETES  





 Gestational diabetes mellitus (GDM), i.e., glucose intolerance with onset or first 
recognition during pregnancy, affects approximately 6% of pregnancies in the United States, 
where the prevalence of GDM has been increasing over time.1,2 GDM is known to be associated 
with subsequent development of cardiovascular risk factors including type 2 diabetes mellitus3-6 
and metabolic syndrome7,8 as well as subclinical atherosclerosis8,9 and manifest cardiovascular 
disease.10-12 Chronic kidney disease (CKD), defined by increased urine albumin excretion 
(albuminuria) and/or reduced estimated glomerular filtration rate (eGFR), affects approximately 
13.6% of US adults (2007-2012).13 Reduced eGFR and albuminuria are independent risk factors 
for all-cause mortality, cardiovascular mortality and end-stage renal disease in the general 
population.14,15  
 The relationship between GDM and subsequent CKD is unclear. Studies have reported an 
association between GDM and early stage CKD16, increased albuminuria among women with a 
history of GDM compared to those without GDM history,17,18 and a higher prevalence of  
 
1This section was previously published in the American Journal of Kidney Diseases. The original citation is as 
follows: Dehmer EW, Phadnis MA, Gunderson EP et al. Association Between Gestational Diabetes and Incident 
Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Kidney Dis 
2018; 71(1): 112-122. Available at doi: 10.1053/j.ajkd.2017.08.015
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albuminuria among women with GDM history who later developed diabetes compared to 
normoglycemic women.19 Other studies have not found differences in albuminuria between 
women with and without GDM history,20,21 although the cross-sectional nature, lack of pre- 
pregnancy measurement of shared risk factors for GDM and CKD, or short duration of follow-up 
time since pregnancy constrained several studies. The aim of this study was to estimate the 
association between GDM and CKD in a longitudinal, prospective population-based study of 
young adults that includes pre-pregnancy assessments of renal function and shared risk factors 






The Coronary Artery Risk Development in Young Adults (CARDIA) study is a 
prospective population-based cohort study that enrolled 5,115 black and white participants aged 
18-30 in 1985-86.22 Follow-up examinations occurred at 2, 5, 7, 10, 15, 20 and 25 years (2010-
11) after the initial examination. Participants were recruited from Birmingham, Alabama; 
Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California. All participants gave 






Sample selection criteria 
 
 Women were asked at each cohort examination whether they were currently pregnant or 
breastfeeding, and about the number of pregnancies, abortions, miscarriages, stillbirths and live 
births since the last exam. The first reported pregnancy > 20 weeks gestation was treated as the 
“index” pregnancy. Women were included in our analytic cohort at the examination prior to the 
index pregnancy and all covariates were selected from that examination. For example, for a 
woman who reported her first birth at CARDIA examination year 15, pre-pregnancy covariates 
were selected from the prior examination in year 10. Urine specimens used to define our 
outcome were collected at CARDIA years 10, 15, 20 and 25. Women who reported a first birth 
prior to the 10 year follow-up examination had their covariates assessed at the first CARDIA 
examination. As shown in Figure 2.1, we excluded women who were parous at the initial 
CARDIA examination (N=1008), women with zero births at the end of CARDIA follow-up 
(examination year 25, N=862), women with CKD prior to or at the baseline examination (N=7), 
women with diabetes mellitus prior to any pregnancy (N=3), women missing measurement of 
baseline CKD or missing measures of both albuminuria and eGFR at all four examinations where 
the outcome was measured (N=25), and women missing data for covariates of interest (N=30). 
Baseline CKD was defined as GFR < 60 ml/min/1.73m2 or self-reported kidney disease other 
than nephrolithiasis or pyelonephritis or a urine albumin to creatinine ratio (ACR) ≥ 25 mg/g 
adjusted for race and gender (urine ACR was not measured at the year 0 exam). Compared to the 
women included in these analyses, women excluded from this study were more likely to be 
older, black, with higher systolic blood pressure, body mass index (BMI), low density 
lipoprotein-cholesterol (LDL-C) levels, eGFR and fasting plasma glucose at enrollment into 
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CARDIA (Table S1, Appendix 2).  The women excluded also were more likely to be smokers, 
have less education, and were more likely to have metabolic syndrome and family history of 
CKD compared with the included study population.   
 
Parity and gestational diabetes mellitus 
 
 At each examination, women were asked if they had diabetes and whether they had 
diabetes only during pregnancy. Self-report of GDM was validated for 200 births between 
baseline and year 10 in 165 CARDIA women by medical record abstraction of laboratory data. 
The sensitivity of reports of ever having GDM was 100% (20 of 20) and specificity was 92% 
(134 of 145).3 
 Women were included if nulliparous (no live births of > 20 weeks gestation) at baseline, 
and transitioned across follow-up time intervals (0-10, >10-15, >15-20, and >20-25) in which the 
number of births (parity) and GDM status were updated. The number of births was cumulative to 
the end of follow up (i.e. examination year of development of CKD or year 25). Once women 
developed GDM, they were classified as having GDM for all subsequent follow-up time (which 
may have included additional pregnancies).  
 
Chronic kidney disease 
 
 Single, untimed urine specimens were collected for measurement of urine albumin and 
creatinine at the years 10, 15, 20 and 25 examinations. Urine albumin was measured by 
nephelometry with a specific anti-albumin monoclonal antibody. In years 10, 15, and 20, urine 
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creatinine was measured by the Jaffe method. In year 25, urine creatinine was measured by the 
Roche enzymatic method. Based on creatinine excretion across 3 days of 24-hour urine 
collections obtained in a CARDIA subsample (N=839),23 calibration constants were used in our 
study to adjust for gender and race-specific differences in urinary creatinine excretion as in 
Murtaugh et al24 using the formula albumin/(k*creatinine) where k=0.88 in Black women (no 
adjustment needed for female gender).  
 Blood samples were drawn from seated participants after at least 8 hours of fasting. 
Serum creatinine was measured at years 0, 10, 15, and 20 by the modified-rate Jaffe method. In 
year 25, creatinine was measured by the Roche enzymatic method. Samples from years 10, 15, 
20 and 25 have been calibrated to National Institute of Standards and Technology Standards as 
recommended by the National Kidney Disease Education Program Laboratory Working Group.25  
Serum creatinine was used in the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation26 to calculate eGFR. The accuracy of the CKD-EPI equation over a range of 
kidney function, clinical characteristics and racial backgrounds has been documented. 26, 27   
 Incident CKD was defined in this study as the development of eGFR < 60 ml/min/1.73 
m2 by the CKD-EPI equation26, or urine ACR ≥ 25 mg/g after one or more births during follow 
up, at any one CARDIA examination in years 10, 15, 20 and 25. In exam years where only one 







Other covariates  
 
 Information on race, sex, and age was self-reported, and trained interviewers assessed 
sociodemographic information including highest level of education completed, medical history, 
family history and medication use. Education level, measured at each examination, was used as a 
measure of socioeconomic status, and categorized as high school or less or more than high 
school. Physical activity was assessed using the interviewer-administered CARDIA Physical 
Activity History assessment at each examination.28 Family history of diabetes mellitus was 
defined by a report of one or more first-degree relatives having diabetes mellitus at one or more 
examinations and family history of CKD was defined as report of one or more first-degree 
relatives with kidney disease.  
 Sitting blood pressure was measured by trained technicians who chose the cuff size 
appropriate to the arm circumference. After an initial 5-minute rest, blood pressure was 
measured three times at 1-minute intervals using the Hawksley (Lancing, Sussex, UK) random-
zero sphygmomanometer through year 15 and the oscillometric Omron (Omron Corp., 
Schaumberg, IL) HEM907XL in years 20 and 25. Calibration equations were established to 
calibrate the Omron measurements to the random-zero device.29 The average of the second and 
third measurements were used. Hypertension was defined as SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg or use of antihypertensive medications. 
 Weight and height at each examination, to the nearest 0.5 cm and nearest 0.2 kg, 
respectively.30 BMI was computed as weight in kilograms divided by squared height in meters.   
 Glucose was measured using the hexokinase ultraviolet method at years 0, 10, 15 and 20 
using hexokinase coupled to glucose-6-phosphate dehydrogenase.31 At year 25 fasting glucose 
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was measured by the Roche Modular P hexokinase method. Blood lipids and lipoproteins were 
measured at each examination.32 Total cholesterol and triglycerides (TG) were measured 
enzymatically, high-density lipoprotein cholesterol (HDL-C) was determined by precipitation 
with dextran sulfate-magnesium chloride, and LDL-C was calculated using the Friedewald 
equation.32 Diabetes mellitus was defined as a fasting glucose ≥ 126 mg/dl, hemoglobin A1c ≥ 
6.5%, 2 hour oral glucose tolerance test (OGTT)  ≥  200 mg/dl and/or use of diabetes 
medications. Glucose intolerance was defined as fasting plasma glucose ≥ 100 mg/dl, 2 hour 
OGTT ≥ 140 mg/dl or use of diabetes medications. Insulin resistance was defined as TG/HDL-C 
≥ 1.7 for black women and TG/HDL-C ≥ 2.2 for white women33 or by the Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR).34,35 Metabolic syndrome was defined as any 3 of 
waist girth > 88 cm, TG ≥ 150 mg/dl, HDL-C < 50 mg/dl, SBP ≥ 130 or DBP ≥ 85 or use of 
antihypertensive medications, and fasting glucose ≥ 100 mg/dl.  
   
Statistical analysis 
 
 Baseline characteristics were compared between women with and without reported GDM 
pregnancies. Pre-pregnancy characteristics correspond to the examination at the beginning of the 
interval during which a woman first reports a birth, where the intervals are CARDIA exam years 
0-10, 10-15, 15-20, 20-25. The probability of not having CKD at each time interval was 
calculated by product limit estimation, and cumulative incidence of CKD within each time 
interval was calculated as 1 minus survival, for parous women with and without exposure to 
GDM.  To account for interval censored data, complementary log-log models were used to 
estimate hazard ratios (HR) of CKD by the method of Prentice and Gloecker,36 comparing 
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women with and without a history of GDM. Confounders were chosen a priori based on a 
directed acyclic graph.37 DAGgity38 was used to determine the minimally sufficient set, which 
included baseline (from the CARDIA exam prior to first pregnancy) age, race,  smoking, 
dyslipidemia, systolic blood pressure, BMI, physical activity score, and education level (for 
socioeconomic status) as well as any report of family history of diabetes. Additionally, baseline 
fasting glucose and eGFR were included in the adjusted model. Effect measure modification 
between race and the exposure was calculated by the addition of an interaction term to each 
model and considered significant for likelihood ratio tests (LRT) with p-values less than 0.1. To 
analyze change in eGFR over time, percent annualized decline in eGFR was calculated for each 
interval and used as the outcome measure in linear mixed models. Linear mixed models were 
chosen to account for within-subject correlation of repeated measure using the autoregressive (1) 
correlation structure based on corrected Akaike Information Criterion. The same minimally 
sufficient set of baseline confounders was included in the adjusted model, as well as baseline 
fasting glucose and eGFR. Analyses were conducted using SAS version 9.4 (Cary, NC) and type 




 A total of 101/820 (12.3%) of the women in the analytic sample reported a GDM 
pregnancy. Women with GDM were more likely to have family history of diabetes, family 
history of CKD and had higher pre-pregnancy BMI (Table 3.1). There was no difference 
between those with and without GDM for pre-pregnancy age, race, education, eGFR, smoking 
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status, fasting glucose, waist circumference, HDL-C levels, systolic blood pressure, diastolic 
blood pressure and total physical activity score.  
 A total of N=105 incident cases of CKD accrued over mean follow-up time of 20.8 years. 
Of those, 98 had albuminuria only, 4 had decreased eGFR only, and 3 met both CKD criteria. 
Overall, among women with GDM, 17/101 (16.8%) developed CKD compared to 88/719 
(12.2%) without GDM (p=0.2).  Among black women with GDM, 13/42 (31.0%) developed 
CKD compared to 45/289 (15.6%) without GDM (p=0.03). Among white women who reported 
GDM, 4/59 (6.8%) developed CKD compared to 43/430 (10.0%) without GDM (p=0.6). The 
cumulative incidence of CKD at each examination interval was greater among those with GDM 
compared to those without although this result was not statistically significant (Table 3.2). The 
relative hazard of incident CKD was higher among women with GDM compared to parous 
women without a history of GDM, although not statistically significant in the crude model 
(Table 3.3). Adjustment for confounders did not significantly change the result. There was 
evidence of interaction between GDM and race (LRT interaction p=0.06). Among black women, 
the HR (95% confidence interval (CI)) for CKD was 1.96 (1.04, 3.67) for those with GDM vs. 
parous women without GDM.  Among white women, the HR (95% CI) was 0.65 (0.23, 1.83). 
The incidence curves by race and GDM status are presented in Figure 2.  
 We examined whether the development of glucose intolerance, insulin resistance, 
diabetes mellitus, metabolic syndrome, or hypertension contributed to explain the association 
between GDM and CKD. Black women were more likely than white women to develop insulin 
resistance as defined by HOMA-IR, metabolic syndrome, hypertension and diabetes mellitus 
(Table 3.4). However, there was no evidence of effect measure modification between interval 
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development of those factors and the association between CKD and GDM in parous black 
women (Table 3.5). 
 No differences were seen in percent-annualized eGFR change between parous women 
with and without GDM (Table 3.6), nor was there evidence of an interaction between race and 




 Normal pregnancy affects renal physiology, resulting in an increase in eGFR and a small 
increase in albuminuria.39 As a sensitivity analysis, measures of CKD were set to missing for any 
examination year when a woman was pregnant, and complementary log-log models were again 
used to estimate hazard ratios (HR) of CKD. Results did not differ from the initial analysis. 
Among black women, the HR (95% CI) was 1.96 (1.04, 3.67) for those with GDM compared to 
those without GDM, while among white women the HR (95% CI) was 0.64 (0.23, 1.81).  
 Women with pregnancies before the initial CARDIA exam who also reported interim 
births during follow-up (N=387) were included in a sensitivity analysis with the main study 
sample (total N=1207 for this analysis). Only births occurring after the initial CARDIA 
examination were considered, and covariates were taken from the CARDIA examination at the 
beginning of the interval during which women reported their first interim birth. Overall, results 
did not differ significantly from the main analysis (see Appendix 2, Tables S2 and S3).  Lastly, 
the analysis was repeated considering only women with albuminuria as the outcome. Results 





GDM was associated with development of CKD, predominantly albuminuria, among 
black women, but not white women in this study of parous women. The association was similar 
after adjusting for pre-pregnancy risk factors for GDM and CKD, including age, systolic blood 
pressure, dyslipidemia, BMI, smoking, socioeconomic status, eGFR, fasting glucose, and 
physical activity level as well as race and family history of diabetes.  
 Biomarkers of endothelial dysfunction are elevated in women with recent GDM 
compared to controls40 and have been shown to predict the development of diabetes independent 
of other known risk factors.41,42 Elevated levels of these biomarkers have also been associated 
with onset and progression of albuminuria as well as increased risk of death among patients with 
type 2 diabetes.43 Given the increased cardiovascular and mortality risk associated with 
albuminuria even in the general population,14,44 several authors have proposed that endothelial 
dysfunction, at least in part, may explain the link between albuminuria, cardiovascular disease 
and mortality.45,46 
 Only a small number of women in this cohort developed eGFR < 60 ml/min/1.73m2 and 
no association was seen between GDM and eGFR decline. Glomerular hyperfiltration, or 
abnormally high eGFR, is seen in early diabetic kidney disease along with albuminuria, and may 
predict progressive diabetic nephropathy.47-49 Although we used the CKD-EPI equation in our 
study, as it was developed to be more accurate at higher eGFR levels,26 among diabetics this 
equation and other estimation formulas may fail to detect hyperfiltration and underestimate 
eGFR decline when compared to measured GFR.50   
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 A prior, although cross-sectional analysis, reported results similar to ours. Women in the 
Kidney Early Evaluation Program (KEEP) with self-reported GDM, but without subsequent 
diabetes, had higher odds of microalbuminuria compared to women without any diabetes 
history.16 An interaction with race and GDM was also seen in the KEEP population, with the 
association between GDM and albuminuria found in black women, but not white women. 
Another cross-sectional analysis of women with GDM without subsequent diabetes in the 
National Health and Nutrition Examination was equivocal in relating microalbuminuria to 
GDM.18 The divergent results in the latter two studies may reflect differences in age of the 
women with GDM history (mean age 32.2 years in NHANES and 51.5 years in KEEP), and the 
population-based design of NHANES versus the kidney disease risk setting in KEEP.   
 Several studies have shown greater risk for incident type 2 diabetes among black women 
with GDM history compared to white women with GDM history.5,6 Diabetes is a well-
established risk factor for CKD,51,52 and development of type 2 diabetes mellitus after a GDM 
pregnancy could explain the association between GDM and incident CKD. Go et al19 evaluated a 
cohort of 289 black women with GDM at a median of 11 years after delivery and reported a 
microalbuminuria prevalence of 11% in normoglycemic women versus 36% in women who 
developed overt DM after GDM. Kew et al21 tested women who were 3 years postpartum, and 
found an association between current glucose intolerance and elevated urine ACR, but not GDM 
and microalbuminuria, although glucose intolerance was treated as a confounder of the 
association between GDM and microalbuminuria. We consider post-partum development of 
glucose intolerance and type 2 diabetes mellitus to be an intermediate on the causal pathway 
between GDM and CKD, and did not adjustment for it to avoid introducing bias.53,54 The 
presence of glucose intolerance, insulin resistance, diabetes mellitus, and metabolic syndrome 
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prior to albuminuria onset did not explain the association between incident albuminuria and 
GDM seen among black women in our study. Other potential explanations for the association 
between GDM and CKD in black women include genetic variation, blood pressure elevation 
following GDM, differences in lactation practices, or differences in the severity of GDM. At 
least one study reported that genes flanking the major histocompatibility complex are associated 
with diabetes mellitus, insulin resistance, hypertension and microalbuminuria in black women 
with a history of GDM.55 Black women have been shown to develop hypertension, a risk factor 
for CKD, more often and more rapidly following a GDM pregnancy compared to white 
women.56 In our cohort, black women were more likely than white women to develop 
hypertension prior to onset of albuminuria, however the presence of hypertension did not seem to 
account for the association between incident albuminuria and GDM seen among black women. 
Higher lactation intensity and longer duration are associated with lower incidence of type 2 
diabetes 2 years after a GDM pregnancy,57 and longer duration of lactation was associated with 
lower incidence of the metabolic syndrome years after a GDM delivery.31 Failure to initiate 
breastfeeding was reported to be higher among black women,58 including a failure to initiate 
breastfeeding after GDM pregnancy.59 The severity of GDM may be greater in black than in 
white women, as they may be more likely to require incident insulin treatment for GDM60 and 
may have more severe complications of GDM.61  
 Among the limitations of this study, GDM was self-reported, although the validity of 
self-reported GDM in CARDIA was high vs. medical record review3, similar to other validation 
studies of self-reported GDM.62,63 Urine specimens were not obtained at the initial CARDIA 
examination, so urine ACR ≥ 25 mg/g at year 0 could not be used as exclusion criteria for 
women who entered the cohort during the interval from year 0 to year 10. Although some 
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women with underlying kidney disease may have been included in the cohort, a high prevalence 
of albuminuria is unlikely in women aged 18-30 years old. Albuminuria was assessed by 
untimed measurements of urinary albumin and creatinine and thus associated with significant 
within-person variability,64 although this practice is supported by strong associations of 
albuminuria using single ACR measurements with	cardiovascular and kidney outcomes 
documented in the literature. 15,65,66 Few women developed reduced eGFR, but results were 
similar when reduced eGFR was removed from the outcome definition. The strengths of this 
study include the racially diverse study population, long duration of follow-up and the 
availability of longitudinal measures of CKD and pre-pregnancy risk factors for both CKD and 
GDM. 
 We conclude that black women in CARDIA with a history of GDM are at risk for 
subsequent albuminuria, independent of traditional risk factors for CKD. Early detection of 
albuminuria allows for both lifestyle and medical interventions, which slow progression of 
disease and reduce cardiovascular risk, yet early stages of CKD are asymptomatic.67  Other 
pregnancy complications, including preeclampsia and gestational hypertension, have been 
associated with incident maternal CKD.68-70 Pregnancy may present a window of opportunity to 
identify women at risk of CKD and implement prevention strategies. Replication of our results 
would suggest that following a GDM pregnancy, black women may benefit from counseling 










































































Table 3.1. Baseline characteristics by GDM status for the sample of 820  
CARDIA women who were nulliparous at the baseline exam and delivered  
one or more births during follow-up (mean 20.8 years) and had measures of CKD 
Variable   Parous, no GDM GDM  p-value 
    N=719   N=101 
Agea (years)   25.8 ± 5.1  25.3 ± 5.1 0.3  
Race 
     Black   289 (40.2)  42 (41.6) 0.8 
     White   430 (59.8)  59 (58.4) 
Education 
     High school or less 179 (24.9)  21 (20.8) 0.5 
     More than high school 540 (75.1)  80 (79.2) 
eGFR (ml/min/1.73m2) 119.2 ± 17.8)  118.4 ± 16.7 0.7 
Smoking status 
     Never   474 (65.9)  62 (61.4) 0.3 
     Former   101 (14.1)  12 (11.9) 
     Current   144 (20.0)  27 (26.7) 
BMI (kg/m2)   23.5 ± 4.9  24.7 ± 5.6 0.03 
Waist circumference (cm) 71.9 ± 9.9  74.3 ± 11.5 0.05 
Fasting glucose (mg/100ml) 80.5 ± 7.3  81.6 ± 9.2 0.3 
HDL-C (mg/dl)  57.5 ± 12.8  55.5 ± 13.0 0.1 
Systolic BP (mmHg)  105.4 ± 9.1  106.2 ± 9.4 0.4 
Diastolic BP (mmHg)  66.2 ± 8.9  67.6 ± 8.6 0.2 
Family history of diabetes  
     Yes    291 (40.5)  58 (57.4) 0.002 
     No    428 (59.5)  43 (42.6) 
Family history of CKD 
     Yes    54 (9.0)  15 (17.7) 0.02 
     No    548 (91.0)  70 (82.4) 
Total physical activity scoreb 316 (174-504)  258 (182-476) 0.3 
 
Note: Values presented are mean ± standard deviation or number (percentage) except where noted. P-values  
were calculated using t-test for continuous variables and by Fisher’s Exact Test or chi-square where  
appropriate for categorical variables except where noted. 
Baseline characteristics were taken from the exam at the beginning of the interval during which CARDIA  
participants reported their first pregnancy, except family history of diabetes which could be reported at any  
exam, and family history of CKD which was only collected at exam year 25. Conversion factors for units:  
Glucose in mg/dl to mmol/L, x0.05551, HDL-C in mg/dl to mmol/L, x0.02586.  
Abbreviations: BP, blood pressure; BMI, body mass index; CARDIA, Coronary Artery Risk Development in  
Young Adults; CKD, chronic kidney disease; GDM, gestational diabetes; eGFR, estimated glomerular  
filtration rate; HDL-C, high density lipoprotein cholesterol 
a. Age at CARDIA exam prior to first reported pregnancy 








Table 3.2. Cumulative incidence of CKD at exam years 0, 10, 15, 20 and  
25 by GDM status among parous CARDIA women with follow-up births  
Exam year # events # at risk Cumulative Incidence (95% CI) 
 
GDM 
0   0   66  0 (0,0) 
10   4   62  0.065 (0.003, 0.126) at year 10 
15   4   72  0.116 (0.040, 0.193) at year 15 
20   4   73  0.165 (0.079, 0.250) at year 20 
25   5   69  0.225 (0.131, 0.320) at year 25 
Parous, no GDM 
0   0  520  0 (0,0) 
10  21  499  0.042 (0.024, 0.060) at year 10 
15  13  547  0.065 (0.044, 0.086) at year 15 
20  34  531  0.125 (0.097, 0.152) at year 20 
25  20  534  0.158 (0.127, 0.188) at year 25 
 
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; CKD,  

































Table 3.3. Hazard ratios with 95% CI for CKD by GDM status among CARDIA women 
nulliparous at baseline who self-reported interim births during mean 20.8 years of 
CARDIA follow-up 
Model   Parous, no GDM GDM   p for interaction 
 
Crude model  1.0 (referent)  1.46 (0.87, 2.45) 
Model 1a   1.0 (referent)  1.33 (0.78, 2.26) 
Model 2b        0.06 
     Black women 1.0 (referent)  1.96 (1.04, 2.67) 
     White women 1.0 (referent)  0.65 (0.23, 1.83)     
 
Note: 820 subjects contributed 2407 observations to each model.  Each subject can contribute one observation for 
each CARDIA exam year she has data available for the outcome. 
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; CKD, 
chronic kidney disease; GDM, gestational  
diabetes. 
a. Model 1 includes variables for age, race, body mass index, smoking, family history of diabetes, fasting glucose, 
baseline estimated glomerular filtration rate, education, high density lipoprotein cholesterol, systolic blood pressure 
and physical activity score.  
































Table 3.4. Cumulative incidence of metabolic dysfunction in parous CARDIA women by 
race 
Variable   Black    White  p-value 
    N=331   N=489   
Glucose intolerancea 
     Yes    121 (36.6)  150 (30.7) 0.08  
     No    210 (63.4)  339 (69.33) 
Insulin resistanceb 
     Yes    141 (42.6)  198 (40.5) 0.6  
     No    190 (57.4)  291 (59.5)  
HOMA-IR 
     >4    114 (34.4)  63 (12.9) <0.0001 
     ≤4    217 (65.6)  426 (87.1)   
HOMA-IR 
     ≥ 2.73   192 (58.0)  145 (29.7) <0.0001 
     <2.73   139 (42.0)  344 (70.4)   
Metabolic syndromec 
     Yes    72 (21.8)  60 (12.3) 0.0005 
     No    259 (78.3)  429 (87.7) 
Diabetes mellitus 
     Yes    41 (12.4)  22 (4.5) <0.0001 
     No    290 (87.6)  467 (95.5) 
Hypertension 
     Yes    115 (34.7)  69 (14.1)  <0.0001 
     No    216 (65.3)  420 (85.9) 
GDM 
     Yes    42 (12.7)  59 (12.1) 0.8 
     No    289 (87.3)  430 (87.9) 
CKD 
     Yes    58 (17.5)  47 (9.6) 0.0013 
     No    273 (82.5)  442 (90.4) 
 
Notes: Values presented are number (percentage). P-values obtained from Fisher’s exact test.  
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CKD, chronic kidney disease; 














Table 3.5. Association between CKD and GDM by presence of glucose intolerance, insulin 
resistance, metabolic syndrome, diabetes, and hypertension in parous black CARDIA 
women  
Variable    no GDM  GDM   LRT p-value 
     HR    HR (95% CI)  for 





     Yes     1.0 (referent)  1.70 (0.71, 4.07) 0.4 
     No     1.0 (referent)  2.98 (1.23, 7.26)  
Insulin resistanceb 
     Yes     1.0 (referent)  1.23 (0.47, 3.23) 0.1 
     No     1.0 (referent)  3.80 (1.69, 8.55) 
HOMA-IR 
     >4     1.0 (referent)  1.83 (0.75, 4.44) 0.6 
     ≤4     1.0 (referent)  2.60 (1.08, 6.28)   
HOMA-IR 
    ≥2.73    1.0 (referent)  1.77 (0.89, 3.91) 0.3 
    <2.73    1.0 (referent)  3.77 (1.41, 10.13)   
Metabolic syndromec 
     Yes     1.0 (referent)  1.55 (0.55, 4.35 0.5 
     No     1.0 (referent)  2.50 (1.15, 5.43)   
Diabetes mellitus 
     Yes     1.0 (referent)  2.05 (0.66, 6.36) 0.9 
     No     1.0 (referent)  1.95 (0.87, 4.37) 
Hypertension 
    Yes     1.0 (referent)  1.39 (0.47, 4.10) 0.3 
     No     1.0 (referent)  2.94 (1.38, 6.26) 
 
Note: 331 subjects contributed 948 observations to each model. Each subject can contribute one observation for each 
CARDIA exam year she has data available for the outcome.  
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; CKD, 
chronic kidney disease; GDM, gestational diabetes; HOMA-IR, Homeostatic Model Assessment of Insulin 















Table 3.6. Differences in percent annualized decline in eGFR for parous CARDIA  
women by GDM history 
Model  no GDM   GDMa   
 
Crude  1.0 (referent)   0.064 (-0.16, 0.29) 
Model 1b 1.0 (referent)     0.013 (-0.21, 0.24) 
     
Note: 820 subjects contributed 2407 observations to each model. Each subject can contribute an observation for each 
CARDIA exam year she has data available for the outcome measurement.  
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; eGFR, estimated glomerular 
filtration rate; GDM, gestational diabetes. 
a. Result may be interpreted as the difference in percent annual decline in eGFR (% ml/min per 1.73 m2).  
b. Model 1 is adjusted for race, age, body mass index, smoking, family history of diabetes, fasting glucose, baseline  
estimated glomerular filtration rate, education, high density lipoprotein cholesterol, systolic blood pressure, and 
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CHAPTER 4. RESULTS – HYPERTENSIVE PREGNANCY  




Hypertensive pregnancy disorders (HPD) include preeclampsia, defined by elevated 
blood pressure and protein in the urine (proteinuria) developing after 20 weeks’ gestation and 
elevated blood pressure without proteinuria that develops after 20 weeks’ gestation, or 
gestational hypertension. HPD are a leading cause of maternal morbidity and mortality 
worldwide.1-3 Rates of preeclampsia and gestational hypertension have increased in the United 
States in recent years.4 HPD are associated with subsequent development of chronic 
hypertension, diabetes, and cardiovascular disease.5-9 Prevalent HPD may identify high risk 
women for future screening and prevention of cardiovascular disease.10    
Chronic kidney disease (CKD) is characterized by proteinuria and/or reduced estimated 
glomerular filtration rate (eGFR). Proteinuria and reduced eGFR are independent risk factors for 
end-stage renal disease, cardiovascular mortality, and all-cause mortality in the general 
population.11,12  Early detection of CKD allows for lifestyle and medical interventions which 
could slow progression of disease and reduce cardiovascular risk, although early stages of CKD 
are asymptomatic.13  
Various studies have found an association between preeclampsia and proteinuria,14-16 
gestational hypertension and CKD,17 HPD and CKD,18 HPD and reduced eGFR,19 HPD and end-
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stage renal disease20,21 and preeclampsia and renal biopsy22 although others have not found an 
association between HDP and kidney function decline23,24  or proteinuria.19,23,24 Some previous 
studies have been limited by an absence of information on pre-pregnancy risk factors, use of 
ICD-9 codes to identify kidney disease, or short follow-up time. Additional longitudinal data on 
the association between HPD and CKD could lead to development of screening and prevention 
strategies for high risk women.25 
The primary aim of this study was to investigate the association between HPD and CKD 
in a prospective population-based cohort study of young adults that includes pre-pregnancy 






The Coronary Artery Risk Development in Young Adults (CARDIA) study is a 
longitudinal cohort study that enrolled 5,115 black and white participants aged 18 to 30 years 
from 4 centers (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA) in 1985 to 
1986. Full details of the study design have been published.26 To date, follow-up examinations 
have occurred at 2, 5, 7, 10, 15, 20, and 25 years (2010-2011) after the initial examination. The 
institutional review boards at each study site approved the study, and all participants gave 




Sample Selection Criteria 
  
The first reported pregnancy longer than 20 weeks’ gestation was treated as the index 
pregnancy. Women were included in our analytic cohort at the examination before the index 
pregnancy, and all covariates were selected from that examination. Women who reported a first 
birth before the 10-year follow-up examination had their covariates assessed at the first CARDIA 
examination. For a woman who reported her first birth at CARDIA examination year 20, pre-
pregnancy covariates were selected from the prior examination in year 15.  
As shown in Figure 2.2, women were excluded who were parous at the initial CARDIA 
examination (n=1,008), women with zero reported births at the CARDIA examination in year 25 
(n=862), women with hypertension prior to any pregnancy (n=29), women with CKD before or 
at the baseline examination or missing measures of CKD at baseline (n=36), women missing 
measures of both albuminuria and eGFR at all 4 examinations at which the outcome was 
measured (n=25), and women missing data for covariates of interest (n=20). Baseline CKD was 
defined as eGFR < 60 ml/min/1.73 m2 or self-reported kidney disease other than nephrolithiasis 
or pyelonephritis or urine albumin-creatinine ratio (ACR) ³ 25 mg/g adjusted for race and sex 
(urine ACR was not measured at the initial examination).  
 
Hypertensive Disorders of Pregnancy 
 
 At each CARDIA examination, women were asked if they were currently pregnant or 
breastfeeding, and about the number of pregnancies in the interval since the last exam. For each 
interval pregnancy, women were asked if they had toxemia, including all of the following: high 
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blood pressure, albumin in the urine and swelling of the ankles, or high blood pressure without 
toxemia. At year 10, an ancillary study was conducted called Hypertension in Pregnancy (HIP). 
In this study, women completed a questionnaire reporting whether they had toxemia or high 
blood pressure during each prior pregnancy. Self-report of an HPD was validated for 366 
pregnancies between baseline and year 10 in 290 CARDIA women by medical record abstraction 
of antepartum and intra-partum blood pressures, urinary protein levels, medication use and 
International Classification of Diseases, 9th Revision (ICD-9) codes. The gold standard for 
preeclampsia was defined as elevated blood pressure and 1+ proteinuria on two or more 
occasions after 20 weeks’ gestation and/or medications specifically used to treat preeclampsia 
before and/or during labor and/or ICD-9 codes 642.4-642.5. Self-report of preeclampsia had a 
sensitivity of 36% and specificity of 93%.27 The gold standard for gestational hypertension was 
defined as elevated blood pressure and absence of 1+ proteinuria on two or more occasions after 
20 weeks’ gestation and/or discharge diagnosis ICD-9 code of 642.3. For any HPD, the 
sensitivity of self-report was 40% with negative predictive value of 90%.28   
 Included women were nulliparous (no live births of > 20 weeks’ gestation) at baseline 
and transitioned across follow-up intervals (0-10, >10-15, >15-20, and >20-25 years) in which 
the number of births and HPD status were updated. The number of births was cumulative to the 
end of follow-up. Once women developed a HPD, they were classified as having a HPD for all 
subsequent follow-up time (which may have included additional pregnancies). Preeclampsia and 
gestational hypertension were combined to form one exposure to increase study power. Both 
have similar risk factors and are associated with increased risk for fetal death and severe neonatal 
morbidity and mortality.29 Nearly half of women diagnosed with gestational hypertension 
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between 24 and 35 weeks of pregnancy go on to develop preeclampsia.30 Thus, preeclampsia and 
gestational hypertension may be related in pathogenesis.  
 
Chronic Kidney Disease 
 
 CARDIA participants provided single untimed urine specimens for measurement of urine 
albumin and creatinine at the year 10, 15, 20 and 25 examinations. Urine albumin was measured 
by nephelometry with a specific anti-albumin monoclonal antibody. In years 10, 15, and 20, 
urine creatinine was measured by the Jaffe method and in year 25 by the Roche enzymatic 
method. Calibration constants were developed based on creatinine excretion across 3 days of 24-
hour urine collections in a CARDIA subsample (n-839).31 These constants were used in our 
study as in Murtaugh et al32 to adjust for sex- and race-specific differences in urine creatinine 
excretion using the formula albumin / (k x creatinine), where k=0.88 in black women (no 
adjustment required for female sex). 
 Blood samples were drawn from seated participants after at least 8 hours of fasting. 
Serum creatinine was measured at years 0, 10, 15, and 20 by the modified-rate Jaffe method and 
in year 25 by the Roche enzymatic method. All samples were calibrated to National Institute of 
Standards and Technology as recommended by the National Kidney Disease Education Program 
Laboratory Working Group.33 eGFR was calculated using the CKD-EPI (CKD Epidemiology 
Collaboration) creatinine equation.34 The accuracy of the CKD-EPI equation in individuals with 
and without kidney disease, with a wide range of kidney function, clinical characteristics and 
racial backgrounds has been documented.34,35  
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 Incident CKD was defined in this study as the development of eGFR < 60 ml/min/1.73m2 
or urine ACR ³ 25 mg/g at any one CARDIA examination in years 10, 15, 20 and 25. In 
examination years in which only one CKD measure was available for an individual, either eGFR 




 Information for age, race and sex was self-reported, and trained interviewers assessed 
sociodemographic information, including highest level of education completed, medical history, 
family history and medication use. Education level, measured at each examination, was used as a 
measure of socioeconomic status and categorized as high school or less or more than high 
school. Physical activity was assessed using the interviewer-administered CARDIA Physical 
Activity History assessment at each examination.36 Family history of CKD was defined as report 
of one or more first-degree relatives with kidney disease. Family history of DM was defined as 
report of one or more first-degree relatives with DM.  
 Sitting blood pressure was measured by trained technicians who chose the cuff size 
appropriate to the arm circumference. After an initial 5-minute rest, blood pressure was 
measured 3 times at 1-minute intervals using the Hawksley (Lancing) random-zero 
sphygmomanometer through year 15 and the oscillometric Omron (Omron Corp) HEM907XL in 
year 20 and 25. The Omron measurements were calibrated to the random-zero device.27 The 
average of the second and third measurements was used. Hypertension was defined as SBP ³ 140 
mm Hg, diastolic blood pressure ³ 90 mm Hg, or use of antihypertensive medications.  
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 Weight and height were measured at each examination to the nearest 0.2 kg and nearest 
0.5 cm, respectively.37 BMI was computed as weight in kilograms divided by height in meters 
squared. BMI was categorized as underweight (BMI < 18.5 kg/m2), normal/healthy weight (18.5 
£ BMI < 25.0), overweight (25.0 £ BMI < 30.0) and obese (BMI ³ 30.0).  
 Glucose was measured using the hexokinase UV method at years 0, 10, 15, 20 using 
hexokinase coupled to glucose-6-phosphate dehydrogenase.38 At year 25, fasting glucose was 
measured by the Roche Modular P hexokinase method. Blood lipids and lipoproteins were 
measured at each examination. Total cholesterol and triglycerides were measured enzymatically, 
high-density lipoprotein (HDL) cholesterol concentration was determined by precipitation with 
dextran sulfate-magnesium chloride, and low-density lipoprotein cholesterol concentration was 
calculated using the Friedewald equation.39 Diabetes mellitus was defined as fasting glucose ³ 
100 mg/dL, 2-hour oral glucose tolerance test result ³ 140 mg/dL, or use of diabetes 
medications. Metabolic syndrome was defined as any 3 of waist girth > 88 cm, triglyceride 
concentration ³ 150 mg/dL, HDL cholesterol concentration < 50 mg/dL, SBP ³ 130 mm Hg or 
diastolic blood pressure ³ 85 mm Hg or use of antihypertensive medications, and fasting glucose 




 Baseline characteristics were compared between women with and without reported HPD. 
Pre-pregnancy characteristics correspond to the examination at the beginning of the interval 
during which a woman first reports a birth, for which the intervals are CARDIA examination 
years 0 to 10, 10 to 15, 15 to 20, and 20 to 25. Hypertension, diabetes mellitus, obesity, and 
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metabolic syndrome at any CARDIA examination was compared between women with and 
without reported HPD. To account for interval-censored data, complementary log-log models 
were used to estimate hazard ratios (HRs) of CKD by the method of Prentice and Gloecker40, 
comparing women with and without a history of HPD. Confounders were chosen a priori based 
on a directed acyclic graph.41 DAGitty42 was used to determine the minimally sufficient set, 
which included baseline (from the CARDIA examination before the first pregnancy) age, race, 
smoking, dyslipidemia, SBP, BMI, physical activity score and education level (for 
socioeconomic status). Additionally, baseline eGFR was included in the adjusted model. As 
normal pregnancy affects renal physiology resulting in an increase in eGFR and small increase in 
proteinuria,43 measures of CKD were set to missing for any examination year when a woman 
was pregnant. Effect measure modification between race and the exposure was calculated by the 
addition of an interaction term to each model and considered significant for likelihood ratio tests 
(LRT) with p-values less than 0.1. Analyses were conducted using SAS, version 9.4 (SAS 




 We used Bayesian methods to correct for the effect of exposure misclassification as 
described in detail by Gustafson44 and MacLehose et al45 demonstrated by Keil et al for time- 
fixed exposures.46 A Bayesian approach was chosen as it could be implemented 
straightforwardly with a complementary log-log model and time-varying exposure. This 
approach uses 3 jointly estimated sub-models to quantify the association between the “true” 
exposure and CKD. One sub-model was used to model the probability of the “true” exposure as a 
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function of all the covariates in a logistic model. To simplify the analysis, the only covariates 
included beyond the effect of HPD and the intervals were age, race and BMI. Prior estimates for 
regression parameters were given normally distributed priors with a mean of 0 and a variance of 
5 (N (0,5)).  The second sub-model estimated the probability of the measured exposure, given the 
“true” exposure and prior parameter estimates of exposure misclassification (sensitivity and false 
positive probability). The third sub-model estimated the probability of a participant in the study 
being diagnosed with CKD as a function of the “true” exposure and all covariates. These 
probabilities were then used to estimate the posterior HR and 95% credible intervals of the HPD-
CKD association. Priors for sensitivity and specificity were derived from the CARDIA 
validation study among nulliparous women at baseline. We also explored priors based on other 
validation studies of HPD reported in the literature (see Table 3.9). Validation studies were 






Compared with women included in these analyses, women excluded were more likely to 
be of older age and black race, with higher eGFR, body mass index (BMI), and systolic blood 
pressure at the initial CARDIA examination (see Appendix 2, Table S4). In addition, excluded 
women had larger waist circumference, lower HDL cholesterol (HDL-C), less years of 
education, and were more likely to have smoking history, family history of kidney disease and 
metabolic syndrome compared to the included study population.    
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Of the 807 women who reported a pregnancy 182 (22.6%) women reported at least one 
complicated by HPD. Among those who reported HPD, 90 reported preeclampsia, 54 reported 
gestational hypertension, and 38 reported one or more pregnancy affected by each. Women with 
HPD had higher baseline BMI, SBP, DBP, and waist circumference, were more likely to be of 
black race and had a lower physical activity score than women without HPD (Table 3.7). There 
was no difference between women who did and did not report HPD for pre-pregnancy age, 
eGFR, education, smoking status, HDL cholesterol and family history of CKD or DM. Women 
who reported HPD were more likely to have hypertension, diabetes mellitus, obesity and 
metabolic syndrome during CARDIA follow-up (Table 3.8).  
 
Association between HPD and CKD 
  
 Among 807 study participants, 101 women (12.5%) developed CKD during mean follow-
up of 22.1 years. Of those, 95 met albuminuria criteria alone, 3 met eGFR criteria alone, and 3 
met both criteria.  Mean urine ACR was 146.4 mg/g for the 98 women who developed 
albuminuria. Of 625 women without self-reported HPD, 70 (11.2%) developed CKD, compared 
to 31/182 (17.0%) of women who reported HPD (p=0.04). The relative hazard of CKD was 
higher among women who reported HPD (HR 1.79 (95% CI 1.17-2.75)) compared to parous 
women without a history of HPD in the crude model. The differences were attenuated in the 
adjusted model (HR 1.55 (95% CI 1.00-2.40)) (Table 3.9). There was no evidence of effect 






For comparison, the HR (95% CI) estimated from a complementary log-log model with 
the misclassified exposure using only race, age, and BMI as covariates was 1.57 (1.02, 2.42), 
which does not differ meaningfully from the fully adjusted model using the misclassified 
exposure (see Table 3.9). Results from our sensitivity analysis to correct for exposure 
misclassification suggested that the HR is sensitive to prior information about misclassification, 
but results using a range of priors were consistently (with one exception) elevated and of greater 
magnitude compared to the HR obtained with the misclassified exposure (see Table 3.10), 
suggesting that our results may be an underestimate of the HPD-CKD association as a result of 
exposure misclassification. Among the women included in our study who had validation data 




Among women in the CARDIA cohort, HPD were associated with increased risk of 
incident maternal CKD, primarily albuminuria. Few women developed reduced eGFR. There are 
several possible explanations for this finding. Glomerular hyperfiltration, or a high eGFR, can be 
an early marker of renal dysfuntion.47 The CKD-EPI equation was used to estimate GFR in this 
study due to its accuracy in young patients and in patients with higher eGFR,48 however it may 
underestimate GFR in patients with glomerular hyperfiltration.49 
 Results similar to ours were seen in a meta-analysis of 7 cohort studies of kidney disease 
after preeclampsia, which found an increased risk of microalbuminuria for women with 
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preeclampsia compared to unaffected women at a weighted mean of 7.1 years postpartum.15 
Women with gestational hypertension were included by several of these studies, observing 
women with preeclampsia were at increased risk of microalbuminuria compared to women with 
gestational hypertension, while women with gestational hypertension were at increased risk of 
microalbuminuria compared to unaffected women.15 This analysis was limited by heterogeneity 
in pooled estimates, small sample size and many of the studies did not include adjustment for 
potential confounders.  
 Subsequently, two larger population-based studies investigating the HPD-CKD 
association have been published which reported results similar to our study. Mannisto et al17 
studied 10,314 women with singleton pregnancies from the Northern Finland Birth Cohort 1966, 
which included all expected births for the year 1966 in 2 northern Finland provinces. Women 
with gestational hypertension had increased risk for CKD (HR 1.91, 95% CI 1.18-3.09) 
compared to normotensive women.17 There was no increased risk for CKD among women with 
preeclampsia compared to normotensive women but there was lower statistical power for this 
analysis.17 CKD was defined by disease-specific International Classification of Diseases (ICD) 
codes recorded in Finnish registers, and ICD codes for kidney disease can fail to identify patients 
with eGFR < 60 ml/min/1.73m2.50-52  
Wang et al21 used reimbursement claims from the Taiwan National Health Insurance 
Program to study incident CKD and ESRD among 26,651 women with a history of HPD 
between 1998 and 2009 compared with 213,397 women frequency matched by age and index 
year of pregnancy, with follow-up through December 31, 2009 for the outcome. Women with 
HPD had greater risk of CKD with an HR of 9.38 (95% CI 7.09-12.4) adjusted for urban status, 
coronary artery disease, congestive heart failure, hyperlipidemia and abruption. Information on 
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individual level data, such as smoking, BMI, and educational level was lacking, and again ICD-9 
codes were used for outcome ascertainment.  
 Paauw et al23 studied 2.782 women participants from the Prevention of Renal and 
Vascular End-stage Disease (PREVEND) study, a population-based observational study of the 
Dutch population with prospective data for kidney function and albuminuria.  This study had 
median follow-up time of 11 years and women were aged 39 to 59 at the first visit. The study 
found that blood pressure was significantly higher in the HPD group compared to the unaffected 
women.53 The use of antihypertensive medication use as well as angiotensin-converting enzyme 
(ACE) inhibitors/angiotensin receptor blockers (ARBs) was also higher at baseline in the HDP 
group.53  The percentage of women developing CKD was comparable in the groups (HR 1.04, 
95% CI 0.79-1.37) although there was a steeper decline in eGFR slope in the HPD group 
compared to the non-HPD group. This pattern disappeared after accounting for ACE 
inhibitor/ARB effect. There was no difference in 24-hour albuminuria between groups.53 ACE 
inhibitors and ARBs are known to reduce proteinuria54-56 so higher ACE inhibitor/ARB use in 
the HPD group could in part explain the findings in this study. 
Limitations of our study to be noted include the self-reported nature of preeclampsia and 
gestational hypertension, with significant misclassification noted in a CARDIA validation study 
using medical record review.27,28 The established definition of preeclampsia has changed over 
time, including the removal of edema from diagnostic criteria and an expanded characterization 
that does not require proteinuria if there is evidence of other end-organ damage.57 We did 
account for exposure misclassification in a sensitivity analysis using a Bayesian approach, based 
on data from the CARDIA validation study as well as other validation studies of HPD reported in 
the literature. Correction for misclassified HPD using a Bayesian approach suggested that 
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exposure misclassification may have resulted in an underestimation of the HPD-CKD 
association. Urine specimens were not obtained at the initial CARDIA examination, so urine 
ACR ³ 25 mg/g at year 0 could not be used as exclusion criteria for women who entered the 
cohort during the interval from year 0 to year 10. Although some women with underlying kidney 
disease may have been included in the cohort, a high prevalence of albuminuria is unlikely in 
women aged 18 to 30 years.58  Albuminuria was assessed by untimed measurements of urinary 
albumin and creatinine which is associated with significant within-person variability.59 This 
practice is supported by strong associations of albuminuria using single ACR measurements with 
cardiovascular and kidney outcomes documented in the literature.12,60 Sample size was small, 
and preeclampsia and gestational hypertension were thus combined to form one exposure, 
although pathogenesis could be different between the two,61-63 as well as between early (<34 
weeks gestation) and late (>34 weeks gestation) preeclampsia.57 Finally, there was no direct 
query about prevalence of autoimmune disorders in CARDIA, which could be an unmeasured 
confounder in the relationship between HPD and CKD. 
 Strengths of this study include the racially diverse study population, long duration of 
follow-up, and the availability of pre-pregnancy risk factors for both CKD and HPD and 
longitudinal measures of CKD.  
The mechanism to account for the association between HPD and CKD is largely 
unknown, but several possibilities exist. First, shared risk factors for HPD and CKD may 
predispose individuals to both conditions. In our study, the association between HPD and CKD is 
attenuated with adjustment for pre-pregnancy risk factors for both conditions, which suggests 
that at these factors explain at least part of the association. Second, kidney disease itself is a risk 
factor for HPD,64  and these conditions may unmask pre-existing subclinical kidney disease. 
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Vikse et al22 found that women with preeclampsia who gave birth to offspring with low birth 
weight and short gestation had increased risk for kidney biopsy later in life. However, 
preeclampsia did not specifically increase the risk of any one type of pathological finding on 
kidney biopsy, which could reflect the exacerbating effect of preeclampsia on kidney disease 
which was undetected prior to pregnancy.  Finally, preeclampsia itself may cause renal injury. It 
is hypothesized that the placenta secretes several anti-angiogenic factors during preeclamptic 
pregnancies, and a resultant imbalance in pro-angiogenic and anti-angiogenic factors may trigger 
abnormal placental vascular development and onset of endothelial dysfunction.65 Glomerular 
endotheliosis, increased vascular permeability and a systemic inflammatory response lead to end-
organ damage and hypoperfusion, which results in the clinical manifestations of hypertension, 
proteinuria and decreased kidney function.66 The glomerular endothelial dysfunction may be 
persistent and lead to development of chronic kidney disease.67 Increased antiangiogenic factors 
are also seen in gestational hypertension68 and a proportion of patients with gestational 
hypertension exhibit the lesions of glomerular endotheliosis.69 More recent data suggests that 
podocyturia (urinary loss of viable glomerular epithelial cells, or podocytes) may be an early 
marker of renal injury in preeclampsia.70 Another hypothesis is that ongoing podocyte damage 
and loss after pregnancy leads to focal segmental glomerulosclerosis which contributes to the 
risk of proteinuria and CKD later in life.70  
In conclusion, HPD are associated with subsequent albuminuria in the mother. Although 
the precise mechanism is yet to be fully elucidated, a pregnancy complicated by an HPD 
suggests an early opportunity to identify women at risk for renal disease. Although some authors 
advocate that women with a history of HPD should be followed for kidney disease later in 
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life,71,72  there are no current guidelines for renal follow-up after an HPD. Further research is 













































Table 3.7 Baseline characteristics by HPD status for the sample of 807 CARDIA women who were 
nulliparous at the baseline exam and delivered one or more births during follow-up and had 
measures of CKD 





Age 25.9 (5.2) 25.3 (4.9) 0.2 
Race 
     Black 









     £High School 








eGFR, ml/min/1.73m2 118.2 (17.6) 120.8 (17.6) 0.09 
Smoking status 
     Never 
     Former 












     Underweight 
     Normal  
     Overweight 















Waist circumference, cm 71.6 (9.2) 73.8 (12.0) 0.02 
HDL cholesterol, mg/dL 57.6 (12.9) 55.9 (12.2) 0.1 
SBP, mm Hg 104.6 (8.7) 107.1 (9.5) 0.0006 
DBP, mm Hg 
GDM 
     Yes 












Family History of CKD  
     Yes 








Family History of DM 
     Yes 
     No 













Note: Characteristics are for the sample of 807 CARDIA women who were nulliparous at baseline examination and 
delivered 1 or more births during follow-up and had measures of CKD. Values for categorical variables are given as 
count (percentage); for continuous variables, as mean ± standard deviation. P values were were calculated using t 
test for continuous variables and Fisher exact test or C2 when appropriate for categorical variables except where 
noted. Baseline characteristics were taken from the examination at the beginning of the interval during which 
women reported their first pregnancy, except family history of CKD, which was collected only at examination year 
25 and gestational diabetes and family history of DM, which could be reported at any exam.  
Abbreviations: BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CKD, 
chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration 
rate; GDM, gestational diabetes mellitus; HDL, high density lipoprotein; HPD, hypertensive pregnancy disorders; 
SBP, systolic blood pressure 





Table 3.8 Characteristics through CARDIA examination year 25 by HPD status for the 
sample of 807 CARDIA women who were nulliparous at the baseline exam and delivered 
one or more births during follow-up and had measures of CKD 






     Yes 








 Diabetes mellitus                  0.03 
      Yes      43 (6.9)         22 (12.1)             
      No       582 (93.1)         160 (87.9) 
 Obesity                   <0.0001 
      Yes      231 (37.0)         103 (56.6)  
      No       394 (63.0)         79 (43.4) 
 Metabolic syndrome                  0.0004 
      Yes      85 (13.6)         46 (25.3) 
      No       540 (86.4)         136 (74.7) 
 Note: Characteristics are for the sample of 807 CARDIA women who were nulliparous at baseline examination and 
delivered 1 or more births during follow-up and had measures of CKD. Values for categorical variables are given as 
count (percentage); P values were calculated using Fisher exact test.  
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CKD, chronic kidney disease; 

























Table 3.9 Hazard ratios for CKD by HPD status among CARDIA women nulliparous at 
baseline who self-reported interim births during mean 22.1 years of CARDIA follow-up 
Model HR (95% CI) 
Parous, no HPD                         HPD  
p value 
Crude model 1.00 (reference)                           1.79 (1.17, 2.75) 0.008 
Model 1a 1.00 (reference)                           1.55 (1.00, 2.40) 0.05 
Note: A total of 807 participants contributed 2,541 observations to each model. Each participant can contribute 1 
observation for each CARDIA examination year she has data available for the outcome.  
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; CKD, 
chronic kidney disease; HPD, hypertensive pregnancy disorders; HR, hazard ratio. 




































Table 3.10 Posterior HR (95% credible intervals) from Bayesian analysis to correct 
exposure misclassification using a selection of validation studies of maternal self-report of 
HPD 



































0.64 0.014 1.86 (1.01, 3.32) 
Carter et al74 Preeclampsia & 
gestational 
hypertension 
0.61 0.055 2.13 (1.04, 4.41) 
Coolman et al75 Preeclampsia 0.87 0.017 1.64 (1.00, 2.63) 
Olson et al76 High blood 
pressure during 
pregnancy 
0.65 0.063 2.10 (1.03, 4.24) 










7.32 (2.81, 19.6) 








3.27 (2.07, 8.06) 
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; HPD, hypertensive pregnancy 
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CHAPTER 5. DISCUSSION 
 
GDM was associated with the development of CKD, predominantly albuminuria, among 
black women, but not white women, in this study of parous women. The association was similar 
after adjusting for pre-pregnancy risk factors for GDM and CKD, including age, SBP, 
dyslipidemia, BMI, smoking, socioeconomic status, eGFR, fasting glucose concentration, and 
physical activity, as well as race and history of diabetes. HPD were also associated with incident 
maternal albuminuria, though no interaction with race was seen. The HPD-CKD relationship was 
attenuated after adjustment for pre-pregnancy risk factors. Few women in these analyses 
developed reduced eGFR. Glomerular hyperfiltration, or a high eGFR, can be an early marker of 
renal dysfunction.1 Paauw et al2 found a high normal eGFR in women with history of early-onset 
preeclampsia compared to women with healthy pregnancies at 10 years postpartum. The CKD-
EPI equation was used to estimate GFR in this study due to its accuracy in young patients and in 
patients with higher eGFR,3 however it may underestimate GFR in patients with glomerular 
hyperfiltration.4 
 
Gestational diabetes mellitus and chronic kidney disease  
 
A prior, although cross-sectional analysis, reported results similar to this analysis with 
regard to the GDM-CKD association. Women in the Kidney Early Evaluation Program (KEEP) 
with self-reported GDM, but without subsequent diabetes, had higher odds of microalbuminuria 
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compared to women without any diabetes history.5 An interaction with race and GDM was also 
seen in the KEEP population, with the association between GDM and albuminuria found in black 
women, but not white women. Another cross-sectional analysis of women with GDM without 
subsequent diabetes in the National Health and Nutrition Examination (NHANES) was equivocal 
in relating microalbuminuria to GDM.6 The divergent results in these two studies may reflect 
differences in the age of women with GDM history (mean age 32.2 years in NHANES and 51.5 
years in KEEP), and the population based design of NHANES versus the kidney disease risk 
setting in KEEP.  
Biomarkers of endothelial dysfunction are elevated in women with recent GDM 
compared to controls7 and have been shown to predict the development of diabetes independent 
of other known risk factors.8,9 Elevated levels of these biomarkers have also been associated with 
onset and progression of albuminuria as well as increased risk of death among patients with type 
2 diabetes.10 Given the increased cardiovascular and mortality risk associated with albuminuria 
even in the general population,11,12 several authors have proposed that endothelial dysfunction, at 
least in part, may explain the link between albuminuria, cardiovascular disease and mortality.13,14  
Several studies have shown greater risk for incident type 2 diabetes among black women 
with GDM history compared to white women with GDM history.15,16 Diabetes is a well-
established risk factor for CKD,17,18 and development of type 2 diabetes mellitus after a GDM 
pregnancy could explain the association between GDM and incident CKD. Go et al19 evaluated a 
cohort of 289 black women with GDM at a median of 11 years after delivery and reported a 
microalbuminuria prevalence of 11% in normoglycemic women versus 36% in women who 
developed overt DM after GDM. Kew et al20 tested women who were 3 years postpartum, and 
found an association between current glucose intolerance and elevated urine ACR, but not GDM 
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and microalbuminuria, although glucose intolerance was treated as a confounder of the 
association between GDM and microalbuminuria. Post-partum development of glucose 
intolerance and type 2 diabetes mellitus is likely an intermediate on the causal pathway between 
GDM and CKD, and adjustment for an intermediate could introduce bias.21,22 The presence of 
glucose intolerance, insulin resistance, diabetes mellitus, and metabolic syndrome prior to 
albuminuria onset did not explain the association between incident albuminuria and GDM seen 
among black women in this analysis.  
Other potential explanations for the association between GDM and CKD in black women 
include genetic variation, blood pressure elevation following GDM, differences in lactation 
practices, or differences in the severity of GDM. At least one study reported that genes flanking 
the major histocompatibility complex are associated with diabetes mellitus, insulin resistance, 
hypertension and microalbuminuria in black women with a history of GDM.23 Black women 
have been shown to develop hypertension, a risk factor for CKD, more often and more rapidly 
following a GDM pregnancy compared to white women.24 In this analysis, black women were 
more likely than white women to develop hypertension prior to onset of albuminuria, however 
the presence of hypertension did not seem to account for the association between incident 
albuminuria and GDM seen among black women. Higher lactation intensity and longer duration 
are associated with lower incidence of type 2 diabetes 2 years after a GDM pregnancy,25 and 
longer duration of lactation was associated with lower incidence of the metabolic syndrome 
years after a GDM delivery.26 Failure to initiate breastfeeding was reported to be higher among 
black women,27 including a failure to initiate breastfeeding after GDM pregnancy.28 The severity 
of GDM may be greater in black than in white women, as they may be more likely to require 
incident insulin treatment for GDM29 and may have more severe complications of GDM.30  
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Hypertensive pregnancy disorders and chronic kidney disease 
 
Results similar to this analysis with regard to the HPD-CKD association were seen in a 
meta-analysis of 7 cohort studies of kidney disease after preeclampsia, which found an increased 
risk of microalbuminuria for women with preeclampsia compared to unaffected women at a 
weighted mean of 7.1 years postpartum.31 Women with gestational hypertension were included 
by several of these studies, observing women with preeclampsia were at increased risk of 
microalbuminuria compared to women with gestational hypertension, while women with 
gestational hypertension were at increased risk of microalbuminuria compared to unaffected 
women.31 This analysis was limited by heterogeneity in pooled estimates, small sample size and 
many of the studies did not include adjustment for potential confounders.  
Subsequently, two larger population-based studies investigating the HPD-CKD 
association have been published which reported results similar to our study. Mannisto et al32 
studied 10,314 women with singleton pregnancies from the Northern Finland Birth Cohort 1966, 
which included all expected births for the year 1966 in 2 northern Finland provinces. Women 
with gestational hypertension had increased risk for CKD (HR 1.91, 95% CI 1.18-3.09) 
compared to normotensive women.32 There was no increased risk for CKD among women with 
preeclampsia compared to normotensive women but there was lower statistical power for this 
analysis.32 CKD was defined by disease-specific International Classification of Diseases (ICD) 
codes recorded in Finnish registers, and ICD codes for kidney disease can fail to identify patients 
with eGFR < 60 ml/min/1.73m2.33-35 
Wang et al36 used reimbursement claims from the Taiwan National Health Insurance 
Program to study incident CKD and ESRD among 26,651 women with a history of HPD 
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between 1998 and 2009 compared with 213,397 women frequency matched by age and index 
year of pregnancy, with follow-up through December 31, 2009 for the outcome. Women with 
HPD had greater risk of CKD with an HR of 9.38 (95% CI 7.09-12.4) adjusted for urban status, 
coronary artery disease, congestive heart failure, hyperlipidemia and abruption. Information on 
individual level data, such as smoking, BMI, and educational level was lacking, and again ICD-9 
codes were used for outcome ascertainment.  
Paauw et al37 studied 2.782 women participants from the Prevention of Renal and 
Vascular End-stage Disease (PREVEND) study, a population-based observational study of the 
Dutch population with prospective data for kidney function and albuminuria.  This study had 
median follow-up time of 11 years and women were aged 39 to 59 at the first visit. The study 
found that blood pressure was significantly higher in the HPD group compared to the unaffected 
women.2 The use of antihypertensive medication use as well as angiotensin-converting enzyme 
(ACE) inhibitors/angiotensin receptor blockers (ARBs) was also higher at baseline in the HDP 
group.2  The percentage of women developing CKD was comparable in the groups (HR 1.04, 
95% CI 0.79-1.37) although there was a steeper decline in eGFR slope in the HPD group 
compared to the non-HPD group. This pattern disappeared after accounting for ACE 
inhibitor/ARB effect. There was no difference in 24-hour albuminuria between groups.2 ACE 
inhibitors and ARBs are known to reduce proteinuria38-40 so higher ACE inhibitor/ARB use in 
the HPD group could in part explain the findings in this study. 
The mechanism to account for the association between HPD and CKD is largely 
unknown, but several possibilities exist. First, shared risk factors for HPD and CKD may 
predispose individuals to both conditions. In our study, the association between HPD and CKD is 
attenuated with adjustment for pre-pregnancy risk factors for both conditions, which suggests 
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that at these factors explain at least part of the association. Second, kidney disease itself is a risk 
factor for HPD,41  and these conditions may unmask pre-existing subclinical kidney disease. 
Vikse et al42 found that women with preeclampsia who gave birth to offspring with low birth 
weight and short gestation had increased risk for kidney biopsy later in life. However, 
preeclampsia did not specifically increase the risk of any one type of pathological finding on 
kidney biopsy, which could reflect the exacerbating effect of preeclampsia on kidney disease 
which was undetected prior to pregnancy.  Finally, preeclampsia itself may cause renal injury. It 
is hypothesized that the placenta secretes several anti-angiogenic factors during preeclamptic 
pregnancies, and a resultant imbalance in pro-angiogenic and anti-angiogenic factors may trigger 
abnormal placental vascular development and onset of endothelial dysfunction.43 Glomerular 
endotheliosis, increased vascular permeability and a systemic inflammatory response lead to end-
organ damage and hypoperfusion, which results in the clinical manifestations of hypertension, 
proteinuria and decreased kidney function.44 The glomerular endothelial dysfunction may be 
persistent and lead to development of chronic kidney disease.45 Increased antiangiogenic factors 
are also seen in gestational hypertension46 and a proportion of patients with gestational 
hypertension exhibit the lesions of glomerular endotheliosis.47 More recent data suggests that 
podocyturia (urinary loss of viable glomerular epithelial cells, or podocytes) may be an early 
marker of renal injury in preeclampsia.48 Another hypothesis is that ongoing podocyte damage 
and loss after pregnancy leads to focal segmental glomerulosclerosis which contributes to the 





Strengths and limitations 
 
The strengths of this study include the racially diverse study population, long duration of 
follow-up and the availability of longitudinal measures of CKD and pre-pregnancy risk factors 
for both CKD and GDM. 
Among the limitations of this study, GDM and HPD were self-reported. The validity of 
self-reported GDM in CARDIA was high vs. medical record review49, similar to other validation 
studies of self-reported GDM.50,51 There was significant misclassification noted for preeclampsia 
and gestational hypertension.52,53 The established definition of preeclampsia has changed over 
time, including the removal of edema from diagnostic criteria and an expanded characterization 
that does not require proteinuria if there is evidence of other end-organ damage.54 We did 
account for exposure misclassification of HPD in a sensitivity analysis using a Bayesian 
approach, based on data from the CARDIA validation study as well as other validation studies of 
HPD reported in the literature. Correction for misclassified HPD using a Bayesian approach 
suggested that exposure misclassification may have resulted in an underestimation of the HPD-
CKD association.  Urine specimens were not obtained at the initial CARDIA examination, so 
urine ACR ≥ 25 mg/g at year 0 could not be used as exclusion criteria for women who entered 
the cohort during the interval from year 0 to year 10. Although some women with underlying 
kidney disease may have been included in the cohort, a high prevalence of albuminuria is 
unlikely in women aged 18-30 years old.55 Albuminuria was assessed by untimed measurements 
of urinary albumin and creatinine and thus associated with significant within-person variability,56 
although this practice is supported by strong associations of albuminuria using single ACR 
measurements with cardiovascular and kidney outcomes documented in the literature. 57-59 
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Sample size was small, and preeclampsia and gestational hypertension were thus combined to 
form one exposure, although pathogenesis could be different between the two,60-62 as well as 
between early (<34 weeks gestation) and late (>34 weeks gestation) preeclampsia.54 Finally, 
there was no direct query about prevalence of autoimmune disorders in CARDIA, which could 
be an unmeasured confounder in the relationship between HPD and CKD. 
 
Conclusions and future directions 
 
The American College of Obstetricians and Gynecologists (ACOG) recommends 
screening at 4-12 weeks postpartum for all women with GDM to identify women with diabetes, 
impaired fasting glucose levels or impaired glucose tolerance.63 Women with GDM should 
follow up with a primary care physician. ACOG recommends that women who had a pregnancy 
affected by GDM and have normal postpartum screening tests undergo repeat testing every 1-3 
years. ACOG suggests that women with a history of preeclampsia and their physicians consider 
lifestyle modifications to manage risk factors for cardiovascular disease during long-term 
postpartum follow-up.41 These recently published guidelines do not specifically mention 
screening and prevention for CKD.  
  The American Heart Association guidelines for cardiovascular disease prevention 
recommend documenting preeclampsia and gestational diabetes as risks factor for cardiovascular 
disease in women, recognizing that pregnancy might offer an early opportunity to identify 
women who might benefit from early assessment of cardiovascular risk and lifestyle changes.64 
Both internists and obstetrician-gynecologists may not understand the need to elicit a pregnancy 
history when assessing women’s cardiovascular risk.65,66 Women who experience a pregnancy 
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complication may not obtain appropriate follow-up. Levine et al67 studied women with 
preeclampsia with severe features and found that only 52.3% attended a 6-week postpartum visit, 
which could result in a missed opportunity for physicians to counsel women on future risk. For 
women who do follow-up after a pregnancy affected by preeclampsia, gynecologists may not 
recommend interventions such as increased physical activity or yearly blood pressure checks.68 
Many women with GDM are not screened for type 2 DM after delivery69 but strategies have been 
associated with higher postpartum screening for GDM, such as clinical protocols for postpartum 
testing, electronic medical records alerts to remind providers of the need for testing, and patient 
reminders.70  
Studies of the effectiveness of screening and interventions to reduce cardiovascular risk 
following a pregnancy affected by gestational diabetes or HPD are limited. Lifestyle 
modifications and medications have been shown to reduce progression of GDM to overt diabetes 
mellitus. Among women with impaired glucose intolerance, women with GDM are more likely 
to develop diabetes compared to women without GDM, and intensive lifestyle intervention 
including physical activity and weight loss as well as metformin reduce the incidence of diabetes 
in women with GDM history.71 Higher lactation intensity and longer duration are associated with 
lower incidence of type 2 diabetes after a GDM pregnancy25, and longer lactation duration is 
associated with a lower metabolic syndrome incidence after a GDM delivery.26 Lactation was 
shown to reduce postpartum blood pressure in women with gestational hypertension, but not 
preeclampsia, 8 months after delivery in a small study.72 An interdisciplinary postpartum 
preeclampsia clinic was established in Canada to educate women about future health 
implications of preeclampsia, assess modifiable cardiovascular risk factors, and provide 
counseling on diet and exercise to achieve weight management. Women are referred at the time 
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of discharge from their delivery. A retrospective chart review of 21 women followed in the clinic 
for six months showed improvement in subject participation in physical activity and a non-
significant improvement in weight an average of 4.4 months postpartum.73 This setting could 
provide the opportunity to test safety, efficacy and cost-effectiveness of similar interventions in 
clinical trials to expand upon this observational work. Further data is required to determine if 
similar interventions may reduce incident CKD following a pregnancy affected by GDM or 
HPD. 
In a US population of young black and white women, GDM was associated with the 
development of CKD among black women, and HPD were associated with the incident CKD in 
all women. Future research is needed to establish appropriate guidelines for screening for renal 
disease after a pregnancy affected by GDM or HPD, to further elucidate mechanisms of the 
association between pregnancy complications and maternal CKD, and to establish effective 
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APPENDIX 2. SUPPLEMENTARY TABLES 
 
Table S1. Initial CARDIA examination characteristics compared for women included and excluded from GDM-CKD analysis 
                              Excluded, by reason for exclusion: 
Variable   Included  Excluded  Parous at year 0 Nulliparous   Other 
    N=820   N=1967  N=1008  N=862   N=97 
Age (years)   23.7 ± 3.7   25.4 ± 3.6   26.0 ± 3.4  24.9 ± 3.6  23.0 ± 3.7 
Race 
     Black   331 (40.4)  1154 (58.7)  734 (72.8)  372 (43.2)  48 (49.5) 
     White   489 (59.6)  812 (41.3)  274 (27.2)  489 (56.8)  49 (50.5) 
Education 
     High school or less  225 (27.4)  832 (42.3)  560 (55.6)  238 (27.6)  34 (35.1) 
     More than high school 595 (72.6)  1135 (57.7)  448 (44.4)  624 (72.4)  63 (65.0) 
eGFR (ml/min/1.73m2)  121.5 ± 16.7  123.8 ± 16.9  126.0 ± 16.9  121.4 ± 16.6  123.0 ± 16.8 
Smoking status 
     Never   537 (65.6)  1033 (52.8)  473 (47.3)  506 (58.8)  54 (57.5) 
     Former   104 (12.7)  284 (14.5)  145 (14.5)  125 (14.5)  14 (14.9) 
     Current   178 (21.7)  638 (32.6)  383 (38.3)  229 (26.6)  26 (27.7) 
BMI (kg/m2)   23.2 ± 4.6  25.1 ± 6.2  25.7 ± 6.4  24.7 ± 5.9  23.7 ± 5.1 
Waist circumference (cm) 71.0 ± 9.1  75.8 ± 12.5  77.2 ± 12.7  74.5 ± 12.3  71.9 ± 10.3 
Fasting glucose (mg/100ml) 79.4 (7.3)  81.8 (9.2)  81.8 (22.1)  81.9 (20.3)  80.4 ± 8.8 
LDL-C (mg/dl)   106.4 ± 30.1  109.2 ± 30.9  109.9 ± 30.8  108.3 ± 30.4  110.4 ± 35.8 
  
Systolic BP (mmHg)  105.7 ± 8.9  107.0 ± 10.2  107.1 ± 10.6  107.0 ± 9.7  106.5 ± 10.3 
Metabolic syndrome    
     Yes    5 (0.6)   47 (2.4)   33 (3.3)   13 (1.5)   1 (1.0) 
     No    815 (99.4)  1920 (97.6)  975 (96.7)  849 (98.5)  96 (99.0) 
Family history of diabetesa  
     Yes    349 (42.6)  902 (45.9)  522 (51.8)  340 (39.4)  40 (41.2) 
     No    471 (57.4)  1065 (54.1)   486 (48.2)  522 (60.6)  57 (58.8) 
Family history of CKDb 
     Yes    69 (10.0)   198 (15.8)  122 (18.1)  71 (13.7)  5 (8.5) 
     No    618 (90.0)  1057 (84.2)   554 (82.0)  449 (86.4)  54 (91.5) 
Total physical activity scorec 321 (319)  264 (316)  230 (290)  311 (344)  365 (412.5) 
Note: Values presented are mean ± standard deviation or number (percentage) except where noted. Percentages may not sum to 100 due to rounding.  Conversion factors for units: Fasting glucose in 
mg/dl to mmol/L, x0.05551. LDL-C in mg/dl to mmol/L, x0.02586.  Abbreviations: BMI, body mass index; BP, blood pressure; CARDIA, Coronary Artery Risk Development in Young Adults; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL-C, low density lipoprotein cholesterol 
a. Family history of diabetes could be reported at any exam b. Missing data as family history of kidney disease was only collected during the year 25 exam. c. Median (IQR) 
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Table S2. Cumulative incidence of CKD by GDM status among  
all CARDIA women reporting births at exam years 0, 10, 15, 20  
and 25 
Interval # events # at risk Incidence (95% CI) 
 
GDM 
0   0   103  0 (0,0) 
10   6   97  0.062 (0.014, 0.110) at year 10 
15   4   111  0.096 (0.039, 0.152) at year 15 
20   4   107  0.129 (0.066, 0.193) at year 20 
25   8   98  0.201 (0.126, 0.275) at year 25 
Parous, no GDM 
0   0  807  0 (0,0) 
10  33  774  0.043 (0.028, 0.057) at year 10 
15  22  791  0.069 (0.052, 0.087) at year 15 
20  48  756  0.128 (0.105, 0.151) at year 20 
25  34  756  0.168 (0.142,0.193) at year 25 
 
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence  
interval; CKD, chronic kidney disease; GDM, gestational diabetes mellitus 
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Table S3. Hazard ratios with 95% CI for CKD by GDM status among all CARDIA women 
reporting births during CARDIA follow-up 
Model   N  Parous, no GDM GDM   p for 
interaction 
 
Crude   3649  1.0 (referent)  1.19 (0.76, 1.87) 
Model 1a   3649  1.0 (referent)  1.18 (0.75, 1.87) 
Model 2b  3649        0.04 
     Black women   1.0 (referent)  1.61 (0.96, 2.70) 
     White women   1.0 (referent)  0.53 (0.19, 1.48)     
     
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; GDM, gestational diabetes; N, number of 
observations 
a. Model 1 is adjusted for age, race, body mass index, smoking, family history of diabetes, fasting glucose, baseline 
estimated glomerular filtration rate, education, high density lipoprotein cholesterol, systolic blood pressure, and 
physical activity score.  


































Table S4. Initial CARDIA examination characteristics compared for women included and excluded from HPD-CKD analysis 
                              Excluded, by reason for exclusion: 
Variable   Included  Excluded  Parous at year 0 Nulliparous   Other 
    N=807   N=1980  N=1008  N=862   N=110 
 
Age (years)   23.8 ± 3.7   25.4 ± 3.6   26.0 ± 3.4  24.9 ± 3.6  22.8 ± 3.6 
Race 
     Black   315 (39.0)  1170 (59.1)  734 (72.8)  372 (43.2)  64 (58.2) 
     White   492 (61.0)  809 (40.9)  274 (27.2)  489 (56.8)  46 (41.8) 
Education 
     High school or less  215 (26.6)  842 (42.5)  560 (55.6)  238 (27.6)  44 (40.0) 
     More than high school 592 (73.4)  1138 (57.5)  448 (44.4)  624 (72.4)  66 (60.0) 
eGFR (ml/min/1.73m2)  121.1 ± 16.7  124.0 ± 16.9  126.0 ± 16.9  121.4 ± 16.6  126.1 ± 16.4 
Smoking status 
     Never   525 (65.1)  1045 (53.1)  473 (47.3)  506 (58.8)  66 (61.7) 
     Former   101 (12.5)  287 (14.6)  145 (14.5)  125 (14.5)  17 (15.9) 
     Current   180 (22.3)  636 (32.3)  383 (38.3)  229 (26.6)  24 (22.4) 
BMI (kg/m2)   23.1 ± 4.5  25.2 ± 6.2  25.7 ± 6.4  24.7 ± 5.9  24.1 ± 5.3 
Waist circumference (cm) 70.9 ± 9.0  75.8 ± 12.5  77.2 ± 12.7  74.5 ± 12.3  72.4 ± 10.9 
Fasting glucose (mg/100ml) 79.4 ± 7.4  81.8 ± 20.8  81.8 ± 22.1  81.9 ± 20.3  80.3 ± 7.9 
HDL-C (mg/dl)   57.2 ± 12.5  55.0 ± 13.1  53.1 ± 12.7  56.9 ± 13.1  57.9 ± 13.6 
  
Systolic BP (mmHg)  105.4 ± 8.8  107.1 ± 10.2  107.1 ± 10.6  107.0 ± 9.7  108.6 ± 10.4 
Metabolic syndrome    
     Yes    4 (0.5)   48 (2.4)   33 (3.3)   13 (1.5)   2 (1.8) 
     No    803 (99.5)  1932 (97.6)  975 (96.7)  849 (98.5)  108 (98.2) 
Family history of diabetesa  
     Yes    342 (42.4)  909 (45.9)  522 (51.8)  340 (39.4)  47 (42.7) 
     No    465 (57.6)  1071 (54.1)   486 (48.2)  522 (60.6)  63 (57.3) 
Family history of CKDb 
     Yes    68 (10.0)   199 (15.8)  122 (18.1)  71 (13.7)  6 (8.96) 
     No    611 (90.0)  1064 (84.2)   554 (82.0)  449 (86.4)  61 (91.0) 
Total physical activity scorec 323 (323)  262 (315)  230 (290)  311 (344)  298 (364) 
Note: Values presented are mean ± standard deviation or number (percentage) except where noted. Percentages may not sum to 100 due to rounding.  Conversion factors for units: Fasting glucose in 
mg/dl to mmol/L, x0.05551. LDL-C in mg/dl to mmol/L, x0.02586.  Abbreviations: BMI, body mass index; BP, blood pressure; CARDIA, Coronary Artery Risk Development in Young Adults; CKD, 
chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol 
a. Family history of diabetes could be reported at any exam b. Missing data as family history of kidney disease was only collected during the year 25 exam.  
c. Median (IQR)
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